- 1 Identification of ultra-rare genetic variants in Pediatric Acute Onset Neuropsychiatric Syndrome
- 2 (PANS) by exome and whole genome sequencing
- 3
- 4 Rosario Trifiletti<sup>\*1</sup>, Herbert M. Lachman<sup>\*2</sup>, Olivia Manusama<sup>3</sup>, Deyou Zheng<sup>4</sup>, Alberto Spalice<sup>5</sup>,
- 5 Pietro Chiurazzi<sup>6</sup>, Allan Schornagel<sup>7</sup>, Andreea M. Serban<sup>8</sup>, Rogier van Wijck<sup>8</sup>, Sigrid
- 6 Swagemakers<sup>8</sup>, Peter J. van der Spek<sup>8</sup>
- 7
- 8 Author Affiliations
- <sup>9</sup> <sup>1</sup>The PANDAS-PANS Institute, Ramsey, N.J., U.S.A
- <sup>10</sup> <sup>2</sup>Department of Psychiatry and Behavioral Sciences, Department of Medicine, Department of
- 11 Genetics, Dominick P. Purpura Department of Neuroscience, Albert Einstein College of
- 12 Medicine. Bronx, New York, U.S.A
- <sup>13</sup> <sup>3</sup>Department of Immunology, Erasmus MC, Rotterdam, Netherlands
- <sup>4</sup>Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
- <sup>5</sup>Department of Pediatrics, Pediatric Neurology, Sapienza University of Rome
- <sup>6</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore,
- 17 Dipartimento Scienze della Vita e Sanità Pubblica, Sezione di Medicina Genomica, and
- 18 Dipartimento Scienze di Laboratorio e Infettivologiche, UOC Genetica Medica, Rome, Italy
- <sup>7</sup>GGZ-Delfland, and Kinderpraktijk Zoetermeer, Netherlands
- <sup>8</sup> Department of Pathology and Clinical Bioinformatics, Erasmus MC, Rotterdam, Netherlands
- 21
- 22 <sup>1,2</sup> These authors contributed equally to this work
- 23
- 24 <sup>\*</sup>corresponding author: <u>Herb.Lachman@einsteinmed.org</u>
- <sup>2</sup> Present address: Department of Psychiatry and Behavioral Sciences, Albert Einstein College
- 26 Medicine. Bronx, New York, 10461, U.S.A
- 27

#### 28 Abstract

29 Pediatric acute onset neuropsychiatric syndrome (PANS) is viewed as an

30 autoimmune/autoinflammatory condition characterized by the abrupt onset of severe 31 neurological and psychiatric symptoms, in particular obsessive-compulsive disorder (OCD), tics, 32 anxiety, mood swings, irritability, and restricted eating, often triggered by infections. However, 33 direct evidence of autoimmunity, infections, or a proinflammatory state is often lacking, and there is no unifying pathogenic pathway. This could be due to underlying genetic heterogeneity, 34 35 which could lead to the development of PANS through different cellular and molecular 36 pathways. Unfortunately, little is known about the genetic basis of PANS. Consequently, we 37 carried out whole exome sequencing (WES) on a U.S. cohort of 386 cases who met diagnostic criteria for PANS, including 133 family triads, and whole genome sequencing (WGS) on ten 38 39 cases from the European Union, who were selected for WGS because of severe PANS 40 symptoms. We focused on identifying potentially deleterious genetic variants that were either de *novo* or ultra-rare with a minor allele frequency (MAF) < 0.001. Candidate mutations were found 41 in 11 genes: PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, 42 43 GABRG2, and SYNGAP1 in a total of 20 cases, which included two sets of siblings, and two or 44 more unrelated subjects with ultra-rare variants in SGCE. NLRC4. RAG1. and SHANK3. The 45 PANS candidate genes we identified separate into two broad functional categories. One group 46 regulates peripheral innate and adaptive immune responses (e.g., PPM1D, CHK2, NLRC4, 47 RAG1, PLCG2), some of which also influence microglia function. Another is expressed primarily 48 at neuronal synapses or directly modulates synaptic function (SHANK3, SYNGAP1, GRIN2A, GABRG2, CACNA1B, SGCE). These neuronal PANS candidate genes are often mutated in 49 autism spectrum disorder, developmental disorders, and myoclonus-dystonia. In fact, eight out 50 51 of 20 cases in this study developed PANS superimposed on a preexisting neurodevelopmental 52 disorder. There is, however, clinical overlap between these two groups and some crossover

53 expression (e.g., some neuronal genes are expressed in immune cells and vice versa) that diminishes the neuronal/immune dichotomy. Genes in both categories are also highly expressed 54 55 in the enteric nervous system, and in the choroid plexus and brain vasculature, suggesting they 56 might contribute to a breach in the blood-CSF barrier and blood-brain barrier (BBB) that would 57 permit the entry of autoantibodies, inflammatory cytokines, chemokines, prostaglandins, and 58 autoantibodies into the brain. Thus, PANS is a genetically heterogeneous condition that can 59 occur as a stand-alone neuropsychiatric condition or co-morbid with neurodevelopmental 60 disorders, with candidate genes functioning at several levels of the neuroinflammatory axis.

61

#### 62 Introduction

The clinical entity known as PANS emerged from problems related to the diagnosis of PANDAS 63 64 (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections). 65 In its original description, PANDAS was characterized by acute onset obsessive-compulsive disorder (OCD) and tics following infection with group A beta-hemolytic streptococcus 66 (GABHS)<sup>1, 2</sup>. The concept of PANS was introduced a decade later to expand the diagnosis to 67 68 include a multitude of acute-onset neuropsychiatric problems and exclude the requirement of GABHS infection and tics (Table 1)<sup>3</sup>. PANDAS is now considered as a subgroup of PANS, 69 70 although some controversy remains. While some investigators have reported the presence of 71 autoantibodies against neuronal antigens and elevated levels of inflammatory cytokines in PANS, these findings are inconsistent and the validity of the Cunningham panel of 5 biomarkers 72 used in diagnosing PANS has been supported in some studies and guestioned in others <sup>4-6</sup>. 73 74 Imaging studies in some PANS cases show local inflammation in the thalamus, basal ganglia, 75 and amygdala, supporting a neuroinflammatory or autoimmune etiology. In addition, many 76 patients respond to immunomodulators, such as non-steroidal anti-inflammatory drugs 77 (NSAIDs), intravenous immunoglobulin (IVIG), corticosteroids, and more recently, the B-cell inhibitor Rituximab<sup>4,8</sup>. However, this finding is controversial as some investigators have 78

expressed concerns about the dearth of large, well-controlled clinical trials <sup>6, 7, 9</sup>. Because of 79 these issues and the lack of consistent, objective biomarkers, many children remain 80 81 undiagnosed and undertreated, adversely affecting both patients and their families, and perhaps 82 contributing to disease chronicity. According to the Stanford PANS Clinic, the median Caregiver 83 Burden Inventory (CBI) during a 1st PANS flare is 37, which is higher than the CBI for those caring for someone with Alzheimer disease and similar to that found in Rett syndrome <sup>10</sup>. 84 85 Although most children with PANS show significant improvement at follow-up, according to a 86 recently published longitudinal study, full remission was rare, and more than one-third were classified as having a chronic course <sup>11</sup>. 87 88 One plausible explanation for the inconsistent findings related to the presence or absence of autoantibodies and inflammatory markers, and the relationship to infectious 89 90 pathogens, is heterogeneity in the infectious diseases other than GABHS, such as Mycoplasma 91 pneumoniae. Borrelia burgdorferi and influenza virus, that might act as autoimmune or proinflammatory triggers <sup>12</sup>. Another possibility is that non-infectious environmental factors that 92 93 activate innate immune pathways (i.e. sterile or non-infectious inflammation), such as oxidative 94 stress, exposure to toxins, or emotional stress, could trigger an abnormal inflammatory 95 response in genetically susceptible children. Finally, heterogeneity in genetic risk factors that 96 cause dysregulation of peripheral immunity, or central neuronal/innate immune pathways could 97 be at play, all leading to a common clinical phenotype. In this model, some genetic subgroups 98 will express classic markers of inflammation or autoantibodies, but not others. However, gene 99 discovery in PANS that can test this model is still in its infancy. Whole exome sequencing (WES) and whole genome sequencing (WGS) are gene 100

discovery tools used by researchers, and increasingly by clinicians, to identify ultra-rare,
 biologically powerful genetic factors underlying disease states. However, such studies have not
 yet been reported in PANS. We now describe the discovery of ultra-rare variants in 11 genes in
 20 PANS cases using WES and WGS technologies.

105

### 106 Subjects and Methods

107 **Subjects.** The European subjects were identified through a call for patients with severe 108 symptoms from a PANS/PANDAS advocacy group called EXPAND after a teenage girl with chronic PANS was found to have an ultra-rare variant in the PPM1D gene by WGS. EXPAND is 109 110 a European advocacy organization for families of children and adolescents with immune-111 mediated neuropsychiatric disorders. Parents, caretakers, or patients signed informed consents 112 approved by the Ethical Committee at Erasmus MC (MEC-2011-253 for control samples and 113 MEC-2021-0359 for PANS patients; IRB/ Human Subject Assurance number/Federal Wide Assurance, FWA00001336). Histories from this cohort were obtained by the participating 114 115 physicians and collated by one of the co-authors (O.M). 116 Cases from the U.S. were obtained from a large private practice run by one of the 117 authors (R.T) devoted to PANS (PANDAS/PANS Institute, Ramsey, NJ). 383 PANS cases and 118 263 controls that included 133 triads had WES carried out by Centogene (see below) (Rostock, 119 Germany). The subjects signed an informed consent by Centogene to which they agreed to 120 provide anonymized genetic information for research purposes. The corresponding author has 121 IRB approval from the Albert Einstein College of Medicine to obtain and analyze deidentified 122 data from human subjects (approval ID, 2000-014). Each case in the U.S. cohort was personally 123 treated by one physician (R.T) who obtained a detailed personal and family history.

To protect patient confidentiality, detailed histories are only available upon request to the corresponding author. The consenting parents and participants have agreed to have the results of this research work published.

127

WGS and WES data analysis. The EU cases were sequenced using DAB nanoball sequencing
 for WGS and Illumina for WES. We implemented ANNOVAR, an efficient software tool that
 utilizes up-to-date information to functionally annotate genetic variants and allele frequencies

131 detected in each patient's genome. In addition to gene-based annotation, ANNOVAR is used for 132 region-based annotations to identify variants in specific genomic regions, such as ultra-133 conserved regions across species (Vista database), predicted transcription factor binding sites 134 (Transfac), segmental duplication regions, genome wide association study (GWAS) hits, 135 database of genomic variants, DNAse I hypersensitivity sites, ENCODE 136 H3K4Me1/H3K4Me3/H3K27Ac/CTCF sites, ChIP-Seg peaks, RNA-Seg peaks, and other 137 annotations in genomic intervals. DNA nanoball sequencing has been applied for WGS to study 138 non-coding regions and in particular variants within the ultra-conserved regulatory regions. This 139 provided highly reliable variant lists that were compared with our selected variants and filtered based on allele frequency in GNOMAD ClinVar (public NCBI repository derived data). Only 140 variants that occurred in patients and are never detected in 597 healthy elderly (Welderly) 141 sample genomes were considered <sup>13</sup>. DNA Nanoball sequencing protocol is detailed in the 142 classic paper by Drmanac et al<sup>14</sup>. The ultra-rare variant assessment was confirmed using 143 144 additional cohorts that have been sequenced by the Erasmus MC team headed by one of us (P.S.). 145

146 The U.S. samples were sequenced by Centogene using double stranded DNA capture 147 baits against approximately 36.5 Mb of the human coding exome (targeting >98% of the coding 148 elements). RefSeg from the human genome build GRCh37/hg19) are used to enrich target 149 regions from fragmented genomic DNA with the Twist Human Core Exome Plus kit. The generated library was sequenced on an Illumina platform to obtain at least 20x coverage depth 150 151 for >98% of the targeted bases. The investigation for relevant variants focused on coding exons 152 and flanking +/-20 intronic nucleotides of genes with a clear gene-phenotype evidence (based 153 on OMIM® information). The resulting variant call (VCF) file was then subjected to a custom 154 pipeline developed at the PANDAS/PANS Institute. For this study, we searched for variants with 155 all of the following properties: 1) minor allele frequency (MAF) of <0.001: 2) American College of 156 Medical Genetics Class 5 or 4 (i.e., "pathogenic" or "likely pathogenic"): 3) among a

157 PANDAS/PANS institute cohort of 383 cases and 263 controls variants that were never

158 observed, with rare exceptions noted, in controls.

159

Network analysis. Functional analysis was performed within Ingenuity Pathway Analysis (IPA)
 (QIAGEN Inc.). All candidate genes were imported in IPA to assess the pathways involved. Two
 additional, unpublished, PANS candidate genes (*MTHC2* and *BID*) were added to the analysis.
 Using the network tool within IPA, a connectivity network was constructed based on the
 IPA/QIAGEN Knowledge Base. Both direct and indirect relationships were used to construct the
 biological network.

166

167 **RNA expression analysis.** The gene expression profiles of the candidate genes were analyzed 168 using several datasets. First, we hypothesized that microglia might play a critical role in the 169 PANS phenotype especially after an inflammatory stimulus. Consequently, a subset of 159 170 autism and pediatric immune disorder genes was analyzed based on a public dataset investigating the effect of LPS on murine microglia and macrophages (GSE102482)<sup>15</sup>. After 171 172 Robust Multichip Average normalization (RMA), a statistical analysis of microarray (SAM) was 173 performed between non-stimulated microglia and LPS-stimulated microglia within OmniViz 174 version 6.1.13.0 (Instem Scientific). The top 15 up-regulated and down-regulated genes were 175 selected for visualization and further analysis. Next, we investigated the gene expression profiles of our 11 PANS-associated 176

candidates in peripheral blood mononuclear cells (PBMCs) under baseline conditions and after
 infection as many patients develop PANS symptoms following infections. Given the rising
 reporting of neuropsychiatric symptoms after COVID-19 infection, we used a recently published
 single cell RNA-seq (sc-RNA-seq) COVID-19 dataset to investigate the gene expression profiles
 <sup>16</sup>. This database contains gene expression patterns in control samples (N=6) and hospitalized
 severe COVID-19 patients (N=7).

183 To investigate the expression of the candidate genes in normal human tissue we used the Genotype-Tissue Expression (GTEx) dataset <sup>17</sup>. We used the GTEx Multi Gene Query 184 available on the GTEx portal to construct the RNA profiles in normal human tissue lineages. 185 186 Finally, as the GTEx portal uses bulk RNA-seq data, we wanted to further investigate the gene 187 expression profiles in more detail. Because neurological and psychiatric symptoms are cardinal 188 in PANS, we were particularly interested in scRNA-seg in brain tissue. scRNA-seg data is not 189 yet available for human brains, however, recently two datasets were published containing scRNA-seq data for adolescent and fetal mouse brains<sup>18, 19</sup>. All candidate genes were 190 investigated in both datasets on the Mouse Brain Atlas portal. 191

192

## 193 Results

194 We identified ultra-rare variants in 11 genes (PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1) in 20 patients who met diagnostic 195 criteria for PANS as established by the PANS Consensus Conference <sup>3</sup>. The ultra-rare variants 196 and brief descriptions of the cases are shown on Figure 1 and Table 2, respectively. In the 197 198 European cohort, two affected siblings (cases 1 and 2) were found with an ultra-rare missense mutation in *PPM1D* (c.131C>G; p.S44W). They inherited the variant from an asymptomatic 199 200 parent who has a family history autoimmune disorders, a common scenario in PANS families <sup>20,</sup> <sup>21</sup>. S44W is a known single nucleotide variant (SNV), rs373862041, with a minor allele 201 frequency (MAF) of 0.000255, based on the TOPMed database of more than 125,000 samples 202 203 <sup>22</sup>. The ultra-rare variant in CACNA1B, found in two affected siblings (cases 3 and 4), is a 48 bp 204 insert at the exon 2 splice donor site (c.390+1) that is predicted to disrupt splicing. It is part of a 205 set of multiallelic insertion variants, rs370237172, that has an overall MAF of 0.017. However, 206 the 48 bp insert is ultra-rare and has not been observed in control data sets. We have been 207 unable to genotype the parents. Interestingly, the same 48 bp insert was identified in a young 208 woman who has been incapacitated with chronic fatigue syndrome (myalgic encephalomyelitis)

Known transmission from a parent in the European cohort was also found in cases 9 and

and anorexia (unpublished observations). This insert shows a 100% hit with a human oral
metagenome assembly (unpublished results from ME/CFS project headed by Dr. Rogier
Louwen, Erasmus MC).

213 10 (NLRC4: c.772T>C; p.C258R; and SGCE: del150 lso; c.450\_452, respectively), which will be 214 discussed below. For the other ultra-rare variants, parental genotypes are not available. 215 Remarkably, in the U.S. cohort, different ultra-rare variants were found in two of the same genes identified in the European cohort (NLRC4 and SGC2), and another, CHK2, codes for a well-216 established PPM1D substrate <sup>23</sup>. A total of four different candidate variants were found in 217 218 NLRC4, the most for any PANS-associated gene. Ultra-rare variants were also found in 219 SHANK3 and RAG1 gene in three patients each. Case 17 has an ultra-rare variant in SHANK3 220 (c.4622C>T, P1541L) and a nonsense mutation in NLRC4 (c.928C>T, p.310X). 221 The finding of ultra-rare mutations in the same genes in unrelated individuals points to a true association. 222 These 11 genes separate into two broad functional categories; those that affect 223 224 peripheral innate and adaptive immune pathways, and those that are expressed primarily in 225 cortical neurons, where they function as synaptic regulators. Some of the immune genes also 226 have significant effects on microglia, and the synaptic genes have all been implicated in other 227 neurological and neurodevelopmental disorders. In addition, several neuronal genes are 228 expressed in the choroid plexus and brain vasculature, suggesting they might contribute to a 229 breach in the blood-CSF barrier and blood-brain barrier (BBB) that accompanies inflammation 230 and infection. However, as described below, this dichotomy between immune and neuronal 231 candidate genes is an over-simplification.

232

212

## 233 PANS candidate genes that primarily function in the peripheral immune system

234 PPM1D, CHK2, PLCG2, RAG1, and NLRC4 have well-established effects on peripheral innate 235 and adaptive immunity. *PPM1D* codes for a serine/threonine phosphatase that negatively 236 regulates p53 and other members of the DNA repair pathway. Somatic *PPM1D* gain of function mutations act as tumor suppressor genes <sup>24-26</sup>. The most common are frameshift and nonsense 237 mutations in exons 5 and 6 that lead to the production of a truncated protein that has a 238 239 stabilizing effect on the retained catalytic portion. Germline exons 5 and 6 truncating mutations are found in children with Jansen de Vries Syndrome (JdVS)<sup>27-31</sup>. JdVS is characterized by 240 intellectual and developmental disabilities (IDD), restricted eating, high pain threshold, ASD, and 241 242 psychiatric symptoms (primarily severe anxiety). Thus, there is some overlap in the clinical features observed in PANS and JdVS (e.g., restricted eating, anxiety). However, IDD is nearly 243 244 universal in JdVS, while the two cases with the S44W variant excelled at school until the 245 development of PANS, which became chronic, leading to persistent neuropsychiatric problems and academic regression. Most children with JdVS have a history of recurrent infections <sup>27</sup>. 246 247 However, no consistent immunological findings have been reported. PPM1D regulates T- and 248 B-lymphocyte differentiation, and cytokine production, with *Ppm1d* deficient mice exhibiting a 249 proinflammatory state following an immune challenge, and an increase in macrophage phagocytosis and autophagy <sup>32-36</sup>. PPM1D has also been found to inhibit intestinal inflammation 250 251 in inflammatory bowel disease and negatively regulates cytokine production in human neutrophils during sepsis <sup>37</sup>. The proinflammatory state in *Ppm1d* null mice mimics that seen in 252 253 PANS patients, suggesting that S44W may induce an exaggerated inflammatory response 254 following an immune challenge through a loss-of-function effect on PPM1D catalytic activity in 255 immune cells. Alternatively, a proinflammatory state could occur through disruption of immune 256 responses caused by other regulatory proteins affected by S44W (see discussion). 257 Similar to PPM1D, CHK2 also codes for a regulator of the DNA repair response by phosphorylating p53<sup>23, 38</sup>. Germline loss of function mutations in the kinase domain are found in

several inherited cancer syndromes <sup>39, 40</sup>. The protein encoded by *CHK*2 is expressed in T-cells 259

258

and regulates IL-2 expression <sup>41</sup>. The rare variant we identified, T410fsX14, is a truncating
mutation in the distal end of the kinase domain and is probably a loss-of-function mutation.
Chk2 inactivation in mouse B cells leads to decreased Ig hypermutation and Ig class switching
<sup>42</sup>, conditions that can, along with a DNA repair defect, lead to immune dysregulation <sup>43-45</sup>.
Defective DNA repair could also underlie the effects of the S44W *PPM1D* variant on immune
function.

The finding of an ultra-rare variant in *PPM1D* and in one of its principal targets, *CHK2*, strongly supports the idea that these are indeed PANS-causing mutations.

*PLCG2* is primarily expressed in B-cells, and gain-of-function mutations have been
 found in patients with severe sterile inflammation, recurrent bacterial infections, autoimmune
 disorders, and humoral immunodeficiency <sup>46-49</sup>. The *PLCG2* Y206F variant maps to the EF hand
 domain that binds calcium. Gain of function mutations in *PLCG2* cause autoinflammatory
 disease through an increase in calcium influx upon B-cell activation <sup>50</sup>. However, the effect of
 Y206F on calcium homeostasis awaits experimental validation.

*NLRC4* codes for a component of the inflammasome, a cytosolic multiprotein complex
 that assembles in response to exogenous or endogenous stressors, thereby playing a major
 role in autoinflammatory diseases and macrophage activation syndrome <sup>51-56</sup>. NLRC4 also
 regulates panoptosis, a recently identified inflammatory programmed cell death pathway, <sup>57</sup> and
 Th17 cells in mice exposed to osmotic stress <sup>58</sup>.

A total of four patients with ultra-rare variants in *NLRC4* were found in our two cohorts (including patient 17 who also has a *SHANK3* variant). Two variants, c.772T>C (p.C258R) and c.928C>T (p.R310X) map to the NACHT domain, which has intrinsic ATPase activity and facilitates self-oligomerization <sup>59</sup>. Gain of function mutations in this region lead to severe hyperinflammatory disorders <sup>55</sup>. Such mutations abrogate autoinhibition by the C-terminal leucine rich region <sup>60</sup>. p.R310X would eliminate this region from the protein. The other two ultrarare variants, c.2309T>C (p.M770T) and c.1799A>G (p.E600G), map to the leucine-rich repeat

region (LRR). Mutations in the LRR affecting the oligomerization interface were recently
 described in two patients with early-onset macrophage activation syndrome <sup>61</sup>.

*RAG1* codes for recombination activating gene 1, which is involved in antibody and T cell receptor V(D)J recombination. RAG1 deficiency leads to abnormalities in T- and B-cell
 tolerance and immune dysregulation, leading to both an increased risk of infection and
 autoimmune problems <sup>62, 63</sup>. Ultra-rare mutations were found in three patients, one of which,
 c.256\_257delAA causes a frameshift in exon 2 (p.K86VfsX33). This variant has previously been
 reported in a heterozygous patient with adult-onset lymphopenia, and in a homozygous patient

with severe combined immunodeficiency (SCID) <sup>64</sup>.

295

## 296 **PANS candidate genes that affect microglia function**

Several of the PANS candidate genes that affect the peripheral immune system also disrupt
microglia function. For example, *Ppm1d* null mice exposed to a hypobaric hypoxic environment
showed an augmented release of inflammatory cytokines from activated microglia <sup>65</sup>. In
microglia derived from iPSCs, PLCG2 expression was found to mediate cell survival,
phagocytosis, and processing of neuronal debris <sup>66</sup>. Finally, NIrc4 regulates apoptotic and
pyroptotic microglial death following ischemic stroke <sup>67, 68</sup>, and astrogliosis and microgliosis in a
mouse model of neuroinflammation <sup>69</sup>.

Additional support for an immune-related effect of a subgroup of PANS-associated candidate genes on microglia function comes from our analysis of a gene expression dataset in LPS-treated mice (GSE102482) <sup>15</sup>. We found that *Sgce* and *Plcg2* were the 2<sup>nd</sup> and 8<sup>th</sup> most downregulated transcripts, and *Nlrc4* the 6<sup>th</sup> most upregulated transcript, in microglia derived from control and LPS-treated mice upon an analysis of a subset of 148 autism and pediatric immune disorder genes (**Figure 2**).

310	In addition to these PANS candidate genes, the expression of Sgce, which will be
311	described in more detail in the next section, is induced in microglia following viral-mediated
312	neuroinflammation in mice <sup>70</sup> . Similarly, we previously found that Sgce expression increased
313	significantly in microglia derived from a mouse model of Rett syndrome, in which innate immune
314	pathways were the most enriched differentially expressed genes <sup>71</sup> .
315	These findings support the idea that a subgroup of PANS candidate genes affect
316	microglia function.
317	
318	Neuronal PANS candidate genes associated with neurological and neurodevelopmental
319	disorders
320	Six PANS candidate genes identified in this study, SHANK3, GRIN2A, SYNGAP1, CACNA1B,
321	GABRG2, and SGCE, are primarily expressed in neurons and variants in these genes have
322	been associated with ASD and other neurodevelopmental disorders. SHANK3, for example,
323	codes for a scaffold protein that regulates the assembly of PSD-95 at glutamatergic excitatory
324	synapses <sup>72-75</sup> . It is among the most commonly mutated genes in ASD and other
325	neurodevelopmental disorders <sup>76-79</sup> . Of the 1003 genes in the Simons Foundation Autism
326	Research Initiative (SFARI) database, SHANK3 has the second highest number of reports.
327	Ultra-rare variants were found in three PANS patients (c.4622C>T, p.1541L; c.3637dupG,
328	p.1213fsX68; c.4776dupC, p.T1593fsX86). Although SHANK3 mutations in ASD are
329	scattered throughout the gene, the majority, including our cases, are found in exon 21, which
330	codes for the proline-rich region (PRR) that binds to and draws other synaptic proteins to the
331	post-synaptic density. ASD-associated variants in SHANK3 disturb mGluR-dependent synaptic
332	plasticity <sup>73</sup> .
333	Case 18 (c.3637dupG, p.1213fsX68) was diagnosed with Phelan-McDermid syndrome,
334	which is usually caused by SHANK3 deletions, developed the sudden onset of severe OCD
335	following bacterial infections. Case 19 (c.4776dupC, p.T1593fsX86) has a history ASD with

minimal verbal ability since early childhood. She developed the sudden onset of OCD and
 aggression as a child that improved dramatically with IVIG, although the baseline ASD and poor
 verbal ability did not improve.

Our finding of co-morbid ASD and PANS in the SHANK3 cases is similar to observations made by Bey et al., who identified *de novo SHANK3* variants in four girls with lifelong, stable developmental delay (DD) who developed subacute, severe psychiatric symptoms resembling PANS, that responded, with varying degrees of success, to immunotherapy <sup>80</sup>. Similarly, in an analysis of 38 individuals with Phelan-McDermid Syndrome, acute regression triggered by infections, changes in hormonal status, and stressful life events were commonly observed, several of whom improved with IVIG <sup>81</sup>.

These findings show that a subgroup of patients with *SHANK3*-associated ASD and developmental disorders have an underlying susceptibility to develop acute onset neuropsychiatric problems that have a neuroinflammatory component.

349 Four other PANS-associated neuronal candidate genes we identified, SYNGAP1, 350 GRIN2A, GABRG2, and CACNA1B mutations have also been found in ASD, epilepsy, and IDD <sup>77, 82-86</sup>. GRIN2A and SYNGAP1 bind to PSD-95. According to the SFARI database, SYNGAP1 351 352 has the ninth highest number of reports. It codes for a postsynaptic Ras GTPase activating protein that regulates developing excitatory synaptic structure and function <sup>87</sup>. Case 8 has a 353 354 nonsense mutation at SYNGAP1 codon 1179. Like the SHANK3 cases, she was diagnosed with ASD as a child, and developed acute onset OCD and food restrictions following a culture 355 356 positive streptococcus pharyngitis.

*GRIN2A* codes for the glutamate ionotropic receptor NMDA type subunit 2A. Mutations have been found in a variety of neurodevelopmental disorders including ASD, epilepsy, and developmental disabilities <sup>84, 88</sup>. The ultra-rare variant found in case 6 maps to a conserved region of the CTD domain, which is involved in mediating intracellular signaling <sup>85</sup>. The CTD region interacts with the MAGUK (membrane-associated guanylate kinase) family of proteins

that bind to PSD-95 and function as important modulators of synaptic plasticity <sup>89</sup>. This subject
 has a history of dyslexia, ADHD, and emotional problems.

364 CACNA1B codes for the voltage-dependent N-type calcium channel subunit alpha-1B, a constituent of the Cav2.2 channel. It too is a regulator of synaptic function that acts at the 365 366 presynaptic terminal to increase neurotransmitter release, which then influences postsynaptic dendritic spine function <sup>90</sup>. In addition to having frequent infections and PANS, Case 3 was 367 368 diagnosed with Hodgkin's lymphoma, nodular sclerosis subtype. He was treated with ABVD, 369 and subsequently, autologous hematological stem cell transplant (HSCT). It is interesting to 370 note that Hodgkin's lymphoma is often found in patients with autoimmune problems and is associated with abnormalities in IL-13 signaling, a cytokine produced by mast cells, eosinophils, 371 nuocvtes. and Th2 cells <sup>92-94</sup>. This patient also has psoriasis, a Th17 associated autoimmune 372 disorder <sup>95, 96</sup>. This suggests the possibility that CACNA1B could have unrecognized effects on 373 374 the immune system by disrupting IL-13 and Th17 signaling leading to PANS, psoriasis, and 375 Hodgkin lymphoma. It is also interesting to note that his neuropsychiatric symptoms have 376 temporarily disappeared following HSCT. However, the follow-up period has only been a few 377 months, so it is too early to determine if the treatment has had a positive impact on his 378 neuropsychiatric symptoms. Autologous HSCT is an emerging technology for treating severe autoimmune disorders <sup>91</sup>. Given these observations, HSCT could prove to be an option for 379 380 treating a small subgroup of chronic, refractory, severely impaired PANS patients.

*GABRG2* codes for the gamma subunit of the GABA-A receptor, a ligand-gated chloride
 channel. It is one of the most mutated genes in febrile seizures and other forms of epilepsy <sup>97, 98</sup>.
 We found a nonsense mutation, c.649C>T; p.Gln217X, in a child with severe PANS (case 5).
 This is the same mutation previously found in sleep-related epilepsy <sup>99</sup>. Case 5 has a history of
 febrile seizures.

386 SGCE is a member of the sarcoglycan family of transmembrane proteins, a component
 387 of the dystrophin-associated glycoprotein complex (DGC). Studies carried out in knockout mice

show that SGCE inhibits excitatory synapse formation, and that loss-of-function mutations lead to an increase in excitatory synapses <sup>100</sup>. The DGC is involved in organizing aquaporin-4containing protein complexes in glia that controls the formation of the glymphatic system. The glymphatic system clears waste from the brain, and impaired glymphatic drainage has been found in neuroinflammation and dementia <sup>101-103</sup>. Ultra-rare mutations in *SGCE* were found in two unrelated subjects, cases 10 and 11.

394 Remarkably, SGCE, CACNA1B, and GRIN2A are well-known for causing Myoclonus-395 Dystonia (M-D), a hyperkinetic movement disorder, which is similar to tics, a diagnostic feature 396 of PANDAS. SGCE, in fact, is the most commonly mutated gene in M-D, with more than onethird of cases having truncating mutations in exon 3, which contains the del150lso in-frame 397 mutation found in case 10<sup>104-106</sup>. Interestingly, patients with myoclonus caused by SGCE 398 399 mutations frequently have co-morbid psychiatric symptoms, including depression, anxiety, bipolar disorder, phobias, alcoholism, and OCD <sup>106</sup>, symptoms that overlap with PANS. 400 401 Similarly, GRIN2A and CACNA1B mutations have been found in dystonic and other rare movement disorders <sup>85, 107-110</sup>. 402

403 These findings suggest that deleterious variants in these "neuronal" genes can result in 404 a range of clinical phenotypes; M-D, ASD, developmental disabilities, epilepsy, and PANS, or 405 PANS co-morbid with these neurodevelopmental problems. It is important to add, however, that 406 case 7 with the PLCG2 ultra-rare variant c.617A>G, p.Y206F, as well as cases 12, 14, and 15, 407 who have mutations in *NLRC4* and *RAG1*, also had preexisting ASD prior to developing PANS. 408 Thus, PANS/ASD co-morbidity is not restricted to cases with variants in genes typically 409 associated with neurodevelopmental disorders. Other genetic factors causing the 410 neurodevelopmental problems, however, cannot be ruled out at this time. 411

## 412 **Connectivity Network**

413 To assess potential functional connections between the PANS candidate genes, we generated 414 a connectivity network to show the direct (solid lines) and indirect interactions (dotted lines) 415 (Figure 3). Included in the network are two additional PANS candidate genes, MTHC2 and BID, 416 identified by one of us (R.T.) by GWAS that will be described in a separate paper. Central to the 417 network is the NF-kB complex transcriptional regulator, which is activated by a variety of immune, infectious, and non-immune (e.g., oxidative stress; toxins) stressors <sup>111, 112</sup>. 418 419 Inappropriate activation of NF-κB has been associated with inflammatory diseases <sup>113</sup>. Directly connected to the NF-kB hub are the PANS candidate genes; PPM1D, PLCG2, NLRC4, RAG1. 420 421 and BID, along with CHK2 and MTCH2, which bind to PPM1D and BID, respectively. This hub represents the set of PANS genes that likely to function through a disruption of peripheral and 422 423 central innate immunity. The PANS candidate genes not directly connected to NF-kB expression 424 are those that are primarily expressed in the brain and cause neurodevelopmental disorders 425 (CACNA1B, SYNGAP1, GRIN2A, SGCE, GABRG2, and SHANK3). 426 Interestingly, CaMKII, a biomarker from the Cunningham panel, is also centrally 427 localized within the connectivity network and has a close relation to multiple candidate genes. 428 429 **Tissue and Cell Expression Pattern of PANS Candidate Genes** To gain further insight into the mechanisms by which the PANS candidate genes lead to 430 431 neuroinflammation, we examined their expression pattern using several gene expression resources, one of which is a single cell RNA-seq (scRNA-seq) database of white blood cells 432 (WBCs)<sup>16</sup>. This database contains gene expression patterns in control samples (N=6) and 433 hospitalized COVID-19 patients (N=7). The candidate genes that have established effects on 434 435 peripheral immune function, PPM1D, CHK2, and RAG1, are expressed in multiple cell types, 436 PLCG2 is primarily expressed in B-cells, and NLRC4 in monocytes and neutrophils (Figure S1). 437 Interestingly, the expression of several genes was significantly affected in the COVID-19 patients. Most notably, a >100-fold increase in NLRC4 expression was found in developing 438

neutrophils. This suggests that PANS-associated *NLRC4* mutations could lead to a marked
alteration in inflammasome function following infections. In addition, a >8-fold increase in *CHK2*(also known as CHEK2) was found in interferon stimulated genes in T4 cells.

442 Although most of the "neuronal" PANS candidate genes are expressed at very low levels in WBCs, there are three notable exceptions. Most striking is GABRG2, which shows marginal 443 444 expression in all WBCs except for T.gd cells ( $v\delta$  T cells) in COVID-19 patients, where a >20-fold 445 increase in expression was found compared with controls. yδ T cells form a minor population of 446 WBCs, but they increase dramatically during infections and play a key role in autoimmunity and immune surveillance <sup>114,115</sup>. Perhaps more importantly from the perspective of PANS is the 447 finding that  $v\delta$  T cells are found in meninges where they secrete the proinflammatory cytokine 448 IL-17a and participate in the development of anxiety-like behavior in mice <sup>116</sup>. 449

450 SYNGAP1 is expressed in many WBC subtypes, especially T cells. Strikingly, like 451 GABRG2, expression in  $\gamma\delta$  T cells increases nearly 4-fold in COVID-19 patients. And SHANK3 452 expression, while negligible in most WBCs, is abundant in a cluster consisting of two groups of 453 cells labeled as stem cells and eosinophils.

These finding suggest that some neuronal PANS candidate genes that typically cause neurodevelopmental disorders have unanticipated effects on immune function and their expression is extremely responsive to an infectious disease stressor. Parenthetically, these findings show that it will be important to monitor the potential impact of SARS-CoV-2 as an infectious disease inducer of PANS.

We next analyzed the cell and tissue expression pattern of each of the PANS candidate
genes in normal human tissues using the GTEx dataset (Figure S2). The gene expression
patterns, based on bulk RNA-seq, generally conform to the functional groups described above
and the connectivity network. The genes affecting peripheral immunity that are connected to the
NF-κB hub are expressed primarily in blood and EB-transformed lymphoblasts, and less so in

the brain, while the genes associated with neurodevelopmental disorders show the opposite
pattern. *PPM1D*, *RAG1*, and *SGCE* are highly expressed in both.

466 To gain further insight into the expression of the PANS candidate genes in the nervous system, we examined the cell type expression pattern in adolescent and fetal mouse brains. 467 468 One of the more striking observations in the adolescent brain is the relatively high level of Chk2 expression in ependymal cells compared with all other brain cell types (Figure 4; see Table S1 469 470 for abbreviation key). Ependymal cells line the ventricles and spinal canal and play an important role in the production of CSF<sup>117</sup>. As part of the choroid plexus, ependymal cells 471 regulate the blood-CSF barrier <sup>118</sup>. The choroid plexus plays a key role in neuroinflammatory 472 and neurodegenerative disorders and serves as a nexus for peripheral T-cells that can infiltrate 473 474 the brain, as well as access, when damaged, to proinflammatory cytokines, complement, and autoantibodies from the circulation to the brain parenchyma <sup>119-121</sup>. *Ppm1d*, Sgce, *Plcg2*, 475 476 Syngap1, and Shank3 are also expressed in these cells, suggesting that their mutated versions

477 could disturb the blood-CSF barrier.

478 Another interesting finding in adolescent nervous system is the relatively high level of 479 expression of *Ppm1d*, *Syngap1*, *Cacna1b*, and *Sgce* throughout the enteric nervous system. 480 The potential implications of this expression pattern will be described in the discussion section. 481 We also examined the single cell gene expression pattern of the PANS candidate genes 482 in the developing mouse brain, considering the fact that several cause neurodevelopmental 483 disorders (Figure S3). One of the more interesting findings is the expression of Shank3, which, 484 as expected, was diffusely expressed throughout the brain in both glutamatergic neurons and GABAergic interneurons. However, the highest levels were seen in the choroid plexus and 485 cerebral vasculature. In fact, all of the PANS candidate genes, with the exception of RAG1 are 486 487 expressed in fetal choroid plexus, cerebral vasculature, and pericytes, with Sgce, Chk2 and 488 *Ppm1d*, along with *Shank3*, being most prominent. This is similar to the single cell expression

pattern seen in adolescent brains (Figure 4), reinforcing the idea that disruption of the blood CSF barrier and/or the BBB is playing a role in the emergence of PANS.

491

## 492 Discussion

Genetic contributions to disease can be divided into common variants that have relatively small
biological effects, which are generally identified by large-scale GWAS, and high impact,
biologically significant ultra-rare variants. So far, no reports have been published in which
common variants were identified, although there is a small, unpublished study derived from a
direct-to-consumer DNA testing service in which five SNPs associated with PANS and PANDAS
were found (see Web Resources), two of which occur in credible candidate genes (rs5029936 in *TNFAIP3*; rs76298532 in *MCPH1*).

500 In the current study, we searched for ultra-rare variants in PANS patients using next 501 generation sequencing. For the European cohort, cases were selected for their severity. The 502 index case was a teenage girl with severe, chronic PANS who was found, along with her 503 affected brother, to have an ultra-rare PPM1D mutation (c.131C>G; p.S44W) (Figure 1). This 504 mutation is upstream of the phosphatase domain and its effect on PPM1D catalytic function is 505 not immediately clear. However, the nearby serine amino acids S40 and S46 could be playing a 506 role the development of PANS in this family. These are substrates for the serine kinases DYRK1A and HIPK2, which cause IDD, ASD, and abnormal feeding behavior when mutated <sup>122-</sup> 507 508 <sup>124</sup>. DYRK1A also has important effects on innate immunity by regulating the balance between Th17 and T regulatory (Treg) cells, T cell subsets involved in the development of autoimmune 509 diseases and inflammation <sup>125-129</sup>. Interestingly, Th17 mediates the effects of Streptococcus on 510 511 neuroinflammation in a mouse model of PANDAS by causing a breach in the BBB, with subsequent brain infiltration of Th17 lymphocytes <sup>125, 130-132</sup>. HIPK2 regulates PPM1D protein 512 levels by inducing its degradation in DNA-damaged cells, triggering activation of the DNA repair 513 pathway <sup>133</sup>. HIPK2 expression increases in LPS-stimulated macrophages, and its knockdown 514

attenuates the expression of inflammatory cytokines <sup>134, 135</sup>. S46 is also a HIPK2 substrate.
Thus, an effect of S44W on immune regulation could be secondary to altered interactions
between DYRK1A and HIPK2 with PPM1D.

518 Following the discovery of this variant, we identified an additional eight other severely 519 affected patients through a PANS/PANDAS advocacy group that primarily operates in the 520 European Union. WGS was carried out, which resulted in the identification of ultra-rare variants 521 in plausible candidate genes in every patient in the European cohort. Although there is a clear 522 ascertainment bias for these participants, the findings of ultra-rare variants in the same genes 523 and other plausible candidates in an unselected, modestly sized population in the United States 524 cohort suggest that severe PANS is often caused by biologically powerful ultra-rare genetic 525 variants. The condition can be viewed as a heterogenous genetically dominant disorder, albeit, 526 with reduced penetrance. Evidence that penetrance is not 100% is seen in several families in 527 whom transmission occurred from a carrier parent who do not have neuropsychiatric problems 528 typical of PANS. The *PPM1D* variant, for example, was inherited from an asymptomatic father 529 who has a family history of autoimmune disorders, In addition, two siblings of case 10 (SGCE 530 (del150 lso; c.450\_452) also inherited the variant. One has asthma, allergies, and contact 531 dermatitis, but no neuropsychiatric problems; The other has similar atopic problems. Although 532 he does not have PANS, he has developed debilitating, recurrent cluster-type headaches. 533 Whether the headaches are a manifestation of neuroinflammation, or vasculitis is not known. 534 Finally, case 9 (NLRC4 c.772T>C; p.C258R), inherited the mutation from a mother who 535 has with a history of psoriasis and arthritis. She was diagnosed with focal epilepsy as an adult 536 but has no history of PANS. A younger sibling with the same variant has a history suggestive of PANS but has not yet been clinically ascertained. 537

538 The lack of complete penetrance is consistent with a small monozygotic twin study in 539 PANDAS that showed a range of different phenotypes, including complete discordance <sup>136</sup>.

Similarly, the MZ twin concordance rate in autoimmune disorders ranges from approximately
 20%-70% depending on the condition <sup>137</sup>.

This suggests that environmental factors are playing a role in PANS. In the case of the 542 543 generation divide between carrier parents and their affected children, changes in the prevalence of certain strains of bacteria and antigenic shifts in viruses implicated as PANS triggers, could 544 545 account for their different clinical outcomes. Borrelia burgdorferi, which causes Lyme disease, is 546 an example of an infectious disease that has markedly increased in prevalence in the past 30 547 vears, while antigenic shifts in viruses that cause influenza or common cold are examples of 548 infectious diseases that are subject to rapid genetic changes. In addition, the current generation of youth might be exposed to non-infectious environmental triggers that were not as prevalent in 549 550 past generations. Although unaffected carrier parents might be exposed to the same infectious 551 agents or non-infectious stressors that are currently triggering PANS flareups in their children, 552 age-related differences in the blood-CSF barrier or BBB could make the adult brain less susceptible <sup>138</sup>. Genetic background and stochastic T cell receptor and IgG gene rearrangement 553 554 could also explain reduced penetrance in families, and discordance in MZ twins.

555 The candidate genes identified in this study can be broadly separated into those that 556 have established effects on peripheral innate and adaptive immunity, and those that affect 557 synaptic function in particular the PSD-95 complex. However, this peripheral vs central 558 dichotomy, which could potentially explain the presence or absence of immune markers and response to immunomodulators, is an oversimplification. First, as noted earlier, several PANS 559 560 candidate genes that have effects on peripheral innate immunity, such as PPM1D, PLCG2, and 561 NLRC4, also affect microglia function and are differentially expressed in those cells following an 562 immune challenge. Second, patients with mutations in genes that function as synaptic regulators, such as SHANK3, can respond to IVIG, as shown by Bey et al <sup>80</sup>. Similarly, our 563 564 cases with ultra-rare variants in SHANK3, CACNA1B, SGCE and GABRG2 also responded to IVIG. Third, as shown in Figure S1, neuronal genes like SHANK3, GABRG2 and SYNGAP1 565

566 show expression patterns that strongly support an adverse effect on immune function, in particular vo T-cells, based on their markedly altered expression during upon an infectious 567 568 disease challenge. Fourth, some of the neuronal PANS candidate genes that have effects on 569 synaptic function, such as SHANK3, SGCE, CHK2, and PPM1D, are also expressed in the 570 choroid plexus and brain vascular endothelium, which could potentially connect peripheral 571 inflammation with neuroinflammation through disruption of the brain/CSF barrier and BBB 572 caused by mutations in these genes. SHANK3 is a cytoskeletal protein that regulates 573 glutamatergic synaptogenesis, but it can also function as a scaffolding protein in epithelial cells<sup>139</sup>. In addition, PPM1D has been found to regulate BBB function and neuroinflammation in 574 575 a co-culture of human brain-microvascular endothelial cells and human astrocytes treated with LPS <sup>140</sup>. 576

577 Expression of PANS candidate genes in the choroid plexus and vascular endothelium 578 during fetal development is also interesting when considering the phenomenon known as 579 maternal immune activation (MIA), a proinflammatory state in pregnancy triggered by infection, maternal autoimmune disorders, and non-infectious peripheral inflammation<sup>141, 142</sup>. The fetal 580 581 brain is vulnerable to changes in the maternal/fetal environment, such as MIA <sup>141-143</sup>, which has been shown in animal models to adversely affect brain development, leading to behaviors and 582 learning difficulties similar to those seen in patients with ASD and schizophrenia <sup>144-152</sup>. 583 584 Consequently, it is conceivable that the pathophysiological process that leads to the development of PANS and co-morbid neurodevelopmental disorders could begin during fetal life 585 586 in some patients and genetic subgroups. 587 An effect on the choroid plexus and vasculature endothelium (and γδ T cells) could also explain the response to IVIG in those patients harboring mutations in the "neuronal" subgroup of 588

589 candidate genes. IVIG can reduce neuroinflammation by affecting T-cell/microglia crosstalk,

590 reducing levels of proinflammatory cytokines, blocking Fcγ receptors, inhibiting complement,

591 and repairing disrupted brain-CSF barriers <sup>153-156</sup>.

592 While extra-neuronal effects of synaptic proteins could have an impact on the development of PANS, their effects on synaptogenesis in the development of PANS should also 593 594 be considered. One possible mechanism is a defect in PSD-95 assembly and glutamate 595 receptor function leading to abnormal synaptic remodeling. This could trigger over-activation of 596 microglia, which in turn would release proinflammatory cytokines, complement, prostaglandins, 597 proteinases, and reactive oxygen species, causing neuroinflammation. An extension of this 598 model is that a similar overactivation of microglia could be driven by a primary, intrinsic defect 599 caused by PANS candidate genes that are highly expressed in microglia, but not neurons (e.g., 600 PLCG2, NLRC4). This is consistent with our finding that Plcg2, Sgce, and Nlrc4 are differentially 601 expressed in LPS-treated microglia (Figure 2). Non-neuronal stimuli that might induce microglia 602 overactivation in PANS is open to speculation, but could include oxidative stress, environmental 603 toxins, and peripheral infection/inflammation.

604 Finally, it is interesting to consider the implications of the finding that several PANS 605 candidate genes are also mutated in D-M, ASD, and other neurodevelopmental disorders. 606 PANS is occurring as an independent phenotype in some of our cases, and as a comorbid trait 607 in others. These comorbid cases are like the SHANK3-mutated patients reported by Bey et al. 608 <sup>80</sup>. Similarly, Jones et al., described eight children with ASD and other neurodevelopmental 609 disorders, with a strong family history of maternal autoimmune thyroid disorders, who presented 610 with infection-induced, abrupt onset of neuropsychiatric symptoms, primarily OCD and tics, along with autistic or global regression<sup>157</sup>. Overall, comorbid ASD and other neuropsychiatric 611 612 disorders were found in nine cases in our study, not including cases 1 and 2 who were typically 613 developing prior to the onset of PANS and the development of chronic symptoms (Table 2)

The development of either PANS, a neurodevelopmental disorder, or PANS comorbid with a neurodevelopmental disorder, could be due to subtle mutation-specific effects on neuronal or immune function, environmental factors (e.g., MIA), or genetic background. A

genetic connection between PANS, D-M, ASD, and other neurodevelopmental disorders also supports the idea that an inflammatory component is involved in the pathogenesis of subgroups of patients with schizophrenia and ASD, as suggested by numerous genetic and molecular studies <sup>157-164</sup>. At the very least, an inflammatory component leading to the abrupt onset of PANS superimposed on a chronic neurodevelopmental disorder is a real phenomenon that needs to be recognized by the medical community because immunological therapies like IVIG could be very helpful.

624

## 625 **Expression of PANS/PANDAS candidate genes in the enteric nervous system**

626 Another aspect of our genetic analysis was the finding that many of the candidate genes we identified are expressed in enteric neurons, which could perhaps explain the abdominal 627 complaints experienced by PANS patients<sup>3</sup>. In addition, enteric expression could be playing a 628 629 direct role in the development of PANS in some genetic subgroups. For example, cholinergic fibers come in close contact with macrophages, plasma cells, and lymphocytes located in the 630 intestinal mucosa, and gut-associated lymphoid tissue <sup>165</sup>. In addition, patients with 631 PANS/PANDAS have been found to have differences in the gut microbiome compared with 632 controls <sup>166, 167</sup>, and an increase in gut-derived LPS and markers of oxidative stress <sup>168</sup>. More 633 634 specific to the candidate genes we identified, several have established effects on the gut. PPM1D, for example, has been found to have a protective effect on oxidation stress-induced gut 635 permeability <sup>165</sup>. In addition, *Shank3* knockout mice have an altered microbiota composition, an 636 increase in LPS levels in the liver, and altered gut permeability <sup>169, 170</sup>. Furthermore, variants in 637 and altered gut permeability NLRC4 have been implicated in inflammatory bowel disease <sup>171, 172</sup>. 638 Overall, the expression of PANS candidate genes in the enteric nervous system fits into 639 640 the emerging idea that disruption of the gut-brain connection and the gut microbiome are

641 involved in the pathogenesis of ASD, neurodegeneration, neuropsychiatric disorders,

642 autoimmune disorders, and PANS <sup>173-177</sup>.

643 In summary, we identified ultra-rare genetic variants in PANS patients that appear to 644 function at multiple levels of the neuroinflammatory circuit, including peripheral and central innate immunity, synaptogenesis, the blood-CSF barrier, and perhaps the enteric nervous 645 system. Dissecting the molecular and cellular pathogenesis of the PANS candidate variants will 646 647 require an analysis in mouse models, as well as patient-specific induced pluripotent stem cells, 648 from which cells of importance in the development of PANS, such as neurons, microglia, 649 astrocytes, neuronal epithelium, vascular endothelium, and gut organoids can be derived. 650 651 **Supplemental Information** 652 Supplemental data include 3 figures and 1 table, Supplemental Note: Case Reports 653 654 Acknowledgments 655 The authors want to thank EXPAND for directing researchers to PANS cases throughout the 656 European Union, and Erika Pedrosa for copy editing the manuscript. HML is supported by the 657 National Institute of Child Health and Human Development NIH/NICHD; P30 HD071593 to the 658 Albert Einstein College of Medicine's Rose F. Kennedy Intellectual and Developmental 659 Disabilities Research Center. The Lachman lab also receives support from the Janice C. 660 Blanchard Family Fund. P.J. van der Spek is supported by EU H2020 grants, an ImmunAID 661 grant (ID: 7792950), and a MOODSTRATIFICATION grant (ID: 754740). The Bioinformatics infrastructure and team is supported by grants from KWF, NWO/ZonMW and the Dutch Heart 662 foundation through the BDVA initiated H2020 Bigmedilytics program on Personalized Medicine. 663 664 Neither the authors nor their academic institutions received payment or services from a third 665 party for any aspect of the submitted work including the study design and manuscript 666 preparation.

- 667 The authors dedicate this paper to Dr. Paul Janssen whose ideas about the role of the
- 668 immune system in tics and psychosis help form the framework for this research project, and to
- 669 participating families for their courage and support.
- 670

671 Declaration of Interests

- 672 The authors declare no competing interests
- 673

### 674 Web Resources

- 675 https://www.nimh.nih.gov/health/publications/pandas/index.shtml
- 676 <u>https://www.expand.care</u>
- 677 <u>http://rstats.immgen.org/Skyline\_COVID-19/skyline.html</u>
- 678 https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis
- 679 https://www.omim.org
- 680 https://www.pandaspansinstitute.com
- 681 https://gene.sfari.org/database/human-gene
- 682 https://www.gtexportal.org/home
- 683 https://genome.ucsc.edu
- 684 http://mousebrain.org
- 685 https://www.phosphosite.org//homeAction.action
- 686 https://osf.io/q4y2k/
- 687

## 688 **References**

- 1. Swedo, S.E., Leonard, H.L., Mittleman, B.B., Allen, A.J., Rapoport, J.L., Dow, S.P., Kanter,
- M.E., Chapman, F., Zabriskie, J. (1997). Identification of children with pediatric autoimmune
- 691 neuropsychiatric disorders associated with streptococcal infections by a marker associated with
- rheumatic fever. Am. J. Psychiatry 154, 110-112.

- 2. Calaprice, D., Tona, J., Parker-Athill, E.C., Murphy, T.K. (2017). A Survey of Pediatric Acute-
- 694 Onset Neuropsychiatric Syndrome Characteristics and Course. J. Child Adolesc.
- 695 Psychopharmacol. 27, 607-618.
- 3. Chang, K., Frankovich, J., Cooperstock, M., Cunningham, M.W., Latimer, M.E., Murphy, T.K.,
- Pasternack, M., Thienemann, M., Williams, K., Walter, J. et al. (2015). Clinical evaluation of
- youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the
- 2013 PANS Consensus Conference. J. Child Adolesc. Psychopharmacol. 25, 3-13.
- 4 Wilbur, C., Bitnun, A., Kronenberg, S., Laxer, R.M., Levy, D.M., Logan, W.J., Shouldice, M.,
- Yeh, E.A. (2019). PANDAS/PANS in childhood: Controversies and evidence. Paediatr. Child.
- 702 Health. 24, 85-91.
- 5. Chiarello, F., Spitoni, S., Hollander, E., Matucci Cerinic, M., Pallanti, S. (2017). An expert
- opinion on PANDAS/PANS: highlights and controversies. Int. J. Psychiatry Clin. Pract. 21, 9198.
- 6. Gilbert, D.L. (2019). Inflammation in Tic Disorders and Obsessive-Compulsive Disorder: Are
  PANS and PANDAS a Path Forward? J. Child Neurol. 34, 598-611.
- 708 7. Zheng, J., Frankovich, J., McKenna, E.S., Rowe, N.C., MacEachern, S.J., Ng, N.N., Tam,
- L.T., Moon, P.K., Gao, J., Thienemann, M. et al. (2020). Association of Pediatric Acute-Onset
- 710 Neuropsychiatric Syndrome With Microstructural Differences in Brain Regions Detected via
- 711 Diffusion-Weighted Magnetic Resonance Imaging. JAMA Netw. Open 3, e204063.
- 8. Vitaliti, G., Tabatabaie, O., Matin, N., Ledda, C., Pavone, P., Lubrano, R., Serra, A., Di
- Mauro, P., Cocuzza, S., Falsaperla, R. (2015). The usefulness of immunotherapy in pediatric
- neurodegenerative disorders: A systematic review of literature data. Hum. Vaccin Immunother.
- 715 11, 2749-2763.

- 9. Melamed, I., Kobayashi, R.H., O'Connor, M., Kobayashi, A.L., Schechterman, A., Heffron, M.,
- 717 Canterberry, S., Miranda, H., Rashid, N. (2021). Evaluation of Intravenous Immunoglobulin in
- 718 Pediatric Acute-Onset Neuropsychiatric Syndrome. J. Child Adolesc. Psychopharmacol. 31,
- 719 118-128.
- 10. Frankovich, J., Leibold, C.M., Farmer, C., Sainani, K., Kamalani, G., Farhadian, B., Willett,
- T., Park, J.M., Sidell, D., Ahmed, S. et al. (2018). The Burden of Caring for a Child or
- Adolescent With Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): An Observational
- Longitudinal Study. J. Clin. Psychiatry 80, 17m12091. doi: 10.4088/JCP.17m12091.
- 11. Gromark, C., Hesselmark, E., Djupedal, I.G., Silverberg, M., Horne, A., Harris, R.A.,
- 725 Serlachius, E., Mataix-Cols, D. (2021). A Two-to-Five Year Follow-Up of a Pediatric Acute-
- 726 Onset Neuropsychiatric Syndrome Cohort. Child Psychiatry Hum. Dev., 1-11.
- 12. Frankovich, J., Thienemann, M., Rana, S., Chang, K. (2015). Five youth with pediatric
- acute-onset neuropsychiatric syndrome of differing etiologies. J. Child Adolesc.
- 729 Psychopharmacol. 25, 31-37.
- 13. Erikson, G.A., Bodian, D.L., Rueda, M., et al. (2016) Whole-genome sequencing of a
- 731 healthy aging cohort. Cell. 2016;165: 1002–1011.
- 14. Drmanac, R., Sparks, A.B., Callow, M.J., Halpern, A.L., Burns, N.L., Kermani, B.G.,
- 733 Carnevali, P., Nazarenko, I., Nilsen, G.B., Yeung, G. et al. (2010). Human genome sequencing
- using unchained base reads on self-assembling DNA nanoarrays. Science 327, 78-81.
- 15. Greenhalgh, A.D., Zarruk, J.G., Healy, L.M., Baskar Jesudasan, S.J., Jhelum, P., Salmon,
- 736 C.K., Formanek, A., Russo, M.V., Antel, J.P., McGavern, D.B. et al. (2018). Peripherally derived
- macrophages modulate microglial function to reduce inflammation after CNS injury. PLoS Biol.
- 738 16, e2005264.

- 16. Wilk, A.J., Rustagi, A., Zhao, N.Q., Roque, J., Martinez-Colon, G.J., McKechnie, J.L., Ivison,
- G.T., Ranganath, T., Vergara, R., Hollis, T., et al. (2020). A single-cell atlas of the peripheral
- immune response to severe COVID-1. Nat Med. Jul; 26(7), 1070–1076.
- 17. GTEx Consortium. (2020). The GTEx Consortium atlas of genetic regulatory effects across
- <sup>743</sup> human tissues. Science Sep 11;369(6509):1318-1330.
- 18. Zeisel, A., Hochgerner, H., Lönnerberg, P., Johnsson, A., Memic, F., van der Zwan, J.,
- Häring, M., Braun, E., Borm, L.E., La Manno, G. et al. (2018). Molecular Architecture of the
- 746 Mouse Nervous System. Cell 174, 999-1014.e22.
- 19. La Manno, G., Siletti, K., Furlan, A., Gyllborg, D., Vinsland, E., Langseth, C.M., Khven, I.,

Johnsson, A., Nilsson, M., Lönnerberg, P. et al. Molecular architecture of the developing mouse
brain. bioRxiv (2020)

- 20. Gagliano, A., Galati, C., Ingrassia, M., Ciuffo, M., Alquino, M.A., Tanca, M.G., Carucci, S.,
- 751 Zuddas, A., Grossi, E. (2020). Pediatric Acute-Onset Neuropsychiatric Syndrome: A Data
- 752 Mining Approach to a Very Specific Constellation of Clinical Variables. J Child Adolesc
- 753 Psychopharmacol. Oct;30(8):495-511.
- 21. Fernell, E., Sundin, M., Fasth, A., Dinkler, L., Galazka, M., Gillberg, C., Johnson, M. (2021).
- 755 Paediatric Acute onset Neuropsychiatric Syndrome: Exploratory study finds no evidence of HLA
- class II association but high rate of autoimmunity in first-degree relatives. Acta Paediatr.
- 22. Burgess, D.J. (2021). The TOPMed genomic resource for human health. Nat. Rev. Genet.
  Apr;22(4):200. doi: 10.1038/s41576-021-00343-x.
- 23. Yoda, A., Xu, X.Z., Onishi, N., Toyoshima, K., Fujimoto, H., Kato, N., Oishi, I., Kondo, T.,
- 760 Minami, Y. (2006). Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-

- terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1. J. Biol.
- 762 Chem. 281, 24847-24862.
- 24. Cardoso, M., Paulo, P., Maia, S., Teixeira, M.R. (2016). Truncating and missense PPM1D
- 764 mutations in early-onset and/or familial/hereditary prostate cancer patients. Genes
- 765 Chromosomes Cancer 55, 954-961.
- 25. Swisher, E.M., Harrell, M.I., Norquist, B.M., Walsh, T., Brady, M., Lee, M., Hershberg, R.,
- 767 Kalli, K.R., Lankes, H., Konnick, E.Q. et al. (2016). Somatic Mosaic Mutations in PPM1D and
- TP53 in the Blood of Women With Ovarian Carcinoma. JAMA Oncol. 2, 370-372.
- 26. Alzahrani, A.S., Murugan, A.K., Qasem, E., Alswailem, M.M., AlGhamdi, B., Moria, Y., Al-
- Hindi, H. (2018). Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid
- 771 Cancer Genome Atlas (TCGA) in a large series of thyroid cancer. Endocrine.
- 27. Jansen, S., Geuer, S., Pfundt, R., Brough, R., Ghongane, P., Herkert, J.C., Marco, E.J.,
- Willemsen, M.H., Kleefstra, T., Hannibal, M. et al. (2017). De Novo Truncating Mutations in the
- Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome. Am. J. Hum.
- 775 Genet. 100, 650-658.
- 28. Lelieveld, S.H., Reijnders, M.R., Pfundt, R., Yntema, H.G., Kamsteeg, E.J., de Vries, P., de
- 777 Vries, B.B., Willemsen, M.H., Kleefstra, T., Lohner, K. et al. (2016). Meta-analysis of 2,104 trios
- provides support for 10 new genes for intellectual disability. Nat. Neurosci. 19, 1194-1196.
- 29. Porrmann, J., Rump, A., Hackmann, K., Di Donato, N., Kahlert, A.K., Wagner, J., Jahn, A.,
- Eger, I., Flury, M., Schrock, E. et al. (2018). Novel truncating PPM1D mutation in a patient with
- 781 intellectual disability. Eur. J. Med. Genet.
- 30. Deciphering Developmental Disorders Study. (2017). Prevalence and architecture of de
- novo mutations in developmental disorders. Nature 542, 433-438.

- 31. Porrmann, J., Rump, A., Hackmann, K., Di Donato, N., Kahlert, A.K., Wagner, J., Jahn, A.,
- Eger, I., Flury, M., Schrock, E. et al. (2019). Novel truncating PPM1D mutation in a patient with
- intellectual disability. Eur. J. Med. Genet. 62, 70-72.
- 787 32. Sun, B., Hu, X., Liu, G., Ma, B., Xu, Y., Yang, T., Shi, J., Yang, F., Li, H., Zhang, L. et al.
- (2014). Phosphatase Wip1 negatively regulates neutrophil migration and inflammation. J.
- 789 Immunol. 192, 1184-1195.
- 33. Yi, W., Hu, X., Chen, Z., Liu, L., Tian, Y., Chen, H., Cong, Y.S., Yang, F., Zhang, L.,
- 791 Rudolph, K.L. et al. (2015). Phosphatase Wip1 controls antigen-independent B-cell
- development in a p53-dependent manner. Blood 126, 620-628.
- 793 34. Liu, G., Hu, X., Sun, B., Yang, T., Shi, J., Zhang, L., Zhao, Y. (2013). Phosphatase Wip1
- negatively regulates neutrophil development through p38 MAPK-STAT1. Blood 121, 519-529.
- 795 35. Tang, Y., Pan, B., Zhou, X., Xiong, K., Gao, Q., Huang, L., Xia, Y., Shen, M., Yang, S., Liu,
- H. et al. (2017). Wip1-dependent modulation of macrophage migration and phagocytosis. RedoxBiol. 13, 665-673.
- 36. Brichkina, A., Bulavin, D.V. (2012). WIP-ing out atherosclerosis with autophagy. Autophagy
  8, 1545-1547.
- 37. Zhang, Q., Zhang, C., Chang, F., Liang, K., Yin, X., Li, X., Zhao, K., Niu, Q., Tian, Z. (2016).
- 801 Wip 1 inhibits intestinal inflammation in inflammatory bowel disease. Cell. Immunol. 310, 63-70.
- 38. Dudgeon, C., Shreeram, S., Tanoue, K., Mazur, S.J., Sayadi, A., Robinson, R.C., Appella,
- E., Bulavin, D.V. (2013). Genetic variants and mutations of PPM1D control the response to DNA
  damage. Cell. Cycle 12, 2656-2664.

- 39. Kleiblova, P., Stolarova, L., Krizova, K., Lhota, F., Hojny, J., Zemankova, P., Havranek, O.,
- Vocka, M., Cerna, M., Lhotova, K. et al. (2019). Identification of deleterious germline CHEK2
- 807 mutations and their association with breast and ovarian cancer. Int. J. Cancer 145, 1782-1797.
- 40. Stolarova, L., Kleiblova, P., Janatova, M., Soukupova, J., Zemankova, P., Macurek, L.,
- Kleibl, Z. (2020). CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than
- 810 Checkmate. Cells 9, 2675. doi: 10.3390/cells9122675.
- 41. Helgeland, H., Gabrielsen, I., Akselsen, H., Sundaram, A.Y.M., Flåm, S.T., Lie, B.A. (2020).
- Transcriptome profiling of human thymic CD4+ and CD8+ T cells compared to primary
- peripheral T cells. BMC Genomics 21, 350-020-6755-1.
- 42. Davari, K., Frankenberger, S., Schmidt, A., Tomi, N.S., Jungnickel, B. (2014). Checkpoint
- kinase 2 is required for efficient immunoglobulin diversification. Cell. Cycle 13, 3659-3669.
- 43. Maffucci, P., Chavez, J., Jurkiw, T.J., O'Brien, P.J., Abbott, J.K., Reynolds, P.R., Worth, A.,
- Notarangelo, L.D., Felgentreff, K., Cortes, P. et al. (2018). Biallelic mutations in DNA ligase 1
- underlie a spectrum of immune deficiencies. J. Clin. Invest. 128, 5489-5504.
- 44. Chen, M.Y., Hsu, W.C., Hsu, S.C., Yang, Y.S., Chuang, T.H., Lin, W.J., Tan, T.H., Su, Y.W.
- 820 (2019). PP4 deficiency leads to DNA replication stress that impairs immunoglobulin class switch
- efficiency. Cell Death Differ. 26, 1221-1234.
- 45. Dujka, M.E., Puebla-Osorio, N., Tavana, O., Sang, M., Zhu, C. (2010). ATM and p53 are
- essential in the cell-cycle containment of DNA breaks during V(D)J recombination in vivo.
- 824 Oncogene 29, 957-965.
- 46. Martín-Nalda, A., Fortuny, C., Rey, L., Bunney, T.D., Alsina, L., Esteve-Solé, A., Bull, D.,
- Anton, M.C., Basagaña, M., Casals, F. et al. (2020). Severe Autoinflammatory Manifestations

- and Antibody Deficiency Due to Novel Hypermorphic PLCG2 Mutations. J. Clin. Immunol. 40,
  987-1000.
- 47. Zhou, Q., Lee, G.S., Brady, J., Datta, S., Katan, M., Sheikh, A., Martins, M.S., Bunney, T.D.,
- 830 Santich, B.H., Moir, S. et al. (2012). A hypermorphic missense mutation in PLCG2, encoding
- phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with
- immunodeficiency. Am. J. Hum. Genet. 91, 713-720.
- 48. Ombrello, M.J., Remmers, E.F., Sun, G., Freeman, A.F., Datta, S., Torabi-Parizi, P.,
- Subramanian, N., Bunney, T.D., Baxendale, R.W., Martins, M.S. et al. (2012). Cold urticaria,
- immunodeficiency, and autoimmunity related to PLCG2 deletions. N. Engl. J. Med. 366, 330-338.
- 49. Yu, P., Constien, R., Dear, N., Katan, M., Hanke, P., Bunney, T.D., Kunder, S., Quintanilla-
- Martinez, L., Huffstadt, U., Schröder, A. et al. (2005). Autoimmunity and inflammation due to a

gain-of-function mutation in phospholipase C gamma 2 that specifically increases external Ca2+

- entry. Immunity 22, 451-465.
- 50. Novice, T., Kariminia, A., Del Bel, K.L., Lu, H., Sharma, M., Lim, C.J., Read, J., Lugt, M.V.,
- Hannibal, M.C., O'Dwyer, D. et al. (2020). A Germline Mutation in the C2 Domain of PLCγ2
- Associated with Gain-of-Function Expands the Phenotype for PLCG2-Related Diseases. J. Clin.
  Immunol. 40, 267-276.
- 51. Alehashemi, S., Goldbach-Mansky, R. (2020). Human Autoinflammatory Diseases Mediated
- by NLRP3-, Pyrin-, NLRP1-, and NLRC4-Inflammasome Dysregulation Updates on Diagnosis,
- Treatment, and the Respective Roles of IL-1 and IL-18. Front. Immunol. 11, 1840.
- 52. Kay, C., Wang, R., Kirkby, M., Man, S.M. (2020). Molecular mechanisms activating the
- 849 NAIP-NLRC4 inflammasome: Implications in infectious disease, autoinflammation, and cancer.
- 850 Immunol. Rev. 297, 67-82.

- 53. Andrade, W.A., Zamboni, D.S. (2020). NLRC4 biology in immunity and inflammation. J.
- 852 Leukoc. Biol. 108, 1117-1127.
- 54. Iqubal, A., Ahmed, M., Ahmad, S., Sahoo, C.R., Iqubal, M.K., Haque, S.E. (2020).
- 854 Environmental neurotoxic pollutants: review. Environ. Sci. Pollut. Res. Int. 27, 41175-41198.
- 55. Liang, J., Alfano, D.N., Squires, J.E., Riley, M.M., Parks, W.T., Kofler, J., El-Gharbawy, A.,
- Madan-Kheterpal, S., Acquaro, R., Picarsic, J. (2017). Novel NLRC4 Mutation Causes a
- 857 Syndrome of Perinatal Autoinflammation With Hemophagocytic Lymphohistiocytosis,
- 858 Hepatosplenomegaly, Fetal Thrombotic Vasculopathy, and Congenital Anemia and Ascites.
- 859 Pediatr. Dev. Pathol. 20, 498-505.
- 56. Romberg, N., Vogel, T.P., Canna, S.W. (2017). NLRC4 inflammasomopathies. Curr. Opin.
- Allergy Clin. Immunol. 17, 398-404.
- 57. Sundaram, B., Kanneganti, T.D. (2021). Advances in Understanding Activation and Function
  of the NLRC4 Inflammasome. Int. J. Mol. Sci. 22, 1048. doi: 10.3390/ijms22031048.
- 58. Ip, W.K., Medzhitov, R. (2015). Macrophages monitor tissue osmolarity and induce
- inflammatory response through NLRP3 and NLRC4 inflammasome activation. Nat. Commun. 6,6931.
- 59. Sandall, C.F., Ziehr, B.K., MacDonald, J.A. (2020). ATP-Binding and Hydrolysis in
- Inflammasome Activation. Molecules 25, 4572. doi: 10.3390/molecules25194572.
- 60. Hu, Z., Yan, C., Liu, P., Huang, Z., Ma, R., Zhang, C., Wang, R., Zhang, Y., Martinon, F.,
- Miao, D. et al. (2013). Crystal structure of NLRC4 reveals its autoinhibition mechanism. Science
  341, 172-175.

- 61. Moghaddas, F., Zeng, P., Zhang, Y., Schützle, H., Brenner, S., Hofmann, S.R., Berner, R.,
- Zhao, Y., Lu, B., Chen, X. et al. (2018). Autoinflammatory mutation in NLRC4 reveals a leucine-
- rich repeat (LRR)-LRR oligomerization interface. J. Allergy Clin. Immunol. 142, 1956-1967.e6.
- 62. Delmonte, O.M., Villa, A., Notarangelo, L.D. (2020). Immune dysregulation in patients with
- 876 RAG deficiency and other forms of combined immune deficiency. Blood 135, 610-619.
- 63. Erman, B., Cipe, F. (2020). Genetic Screening of the Patients with Primary
- 878 Immunodeficiency by Whole-Exome Sequencing. Pediatr Allergy Immunol Pulmonol
- 879 Mar;33(1):19-24.
- 64. Abraham, R.S., Recher, M., Giliani, S., Walter, J.E., Lee, Y.N., Frugoni, F., Maddox, D.E.,
- 881 Kirmani, S., Notarangelo, L.D. (2013). Adult-onset manifestation of idiopathic T-cell
- lymphopenia due to a heterozygous RAG1 mutation. J. Allergy Clin. Immunol. 131, 1421-1423.
- 883 65. Li, D., Zhang, L., Huang, X., Liu, L., He, Y., Xu, L., Zhang, Y., Zhao, T., Wu, L., Zhao, Y. et
- al. (2017). WIP1 Phosphatase Plays a Critical Neuroprotective Role in Brain Injury Induced by
- High-Altitude Hypoxic Inflammation. Neurosci. Bull. 33, 292-298.
- 66. Andreone, B.J., Przybyla, L., Llapashtica, C., Rana, A., Davis, S.S., van Lengerich, B., Lin,
- K., Shi, J., Mei, Y., Astarita, G. et al. (2020). Alzheimer's-associated PLCγ2 is a signaling node
- required for both TREM2 function and the inflammatory response in human microglia. Nat.
- 889 Neurosci. 23, 927-938.
- 67. Poh, L., Kang, S.W., Baik, S.H., Ng, G.Y.Q., She, D.T., Balaganapathy, P., Dheen, S.T.,
- Magnus, T., Gelderblom, M., Sobey, C.G. et al. (2019). Evidence that NLRC4 inflammasome
- mediates apoptotic and pyroptotic microglial death following ischemic stroke. Brain Behav.
- 893 Immun. 75, 34-47.

- 68. Bergsbaken, T., Fink, S.L., Cookson, B.T. (2009). Pyroptosis: host cell death and
- inflammation. Nat. Rev. Microbiol. 7, 99-109.
- 69. Freeman, L., Guo, H., David, C.N., Brickey, W.J., Jha, S., Ting, J.P. (2017). NLR members
- 897 NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes. J. Exp.
- 898 Med. 214, 1351-1370.
- 70. DePaula-Silva, A.B., Gorbea, C., Doty, D.J., Libbey, J.E., Sanchez, J.M.S., Hanak, T.J.,
- 200 Cazalla, D., Fujinami, R.S. (2019). Differential transcriptional profiles identify microglial- and
- 901 macrophage-specific gene markers expressed during virus-induced neuroinflammation. J.
- 902 Neuroinflammation 16, 152-019-1545-x.
- 903 71. Zhao, D., Mokhtari, R., Pedrosa, E., Birnbaum, R., Zheng, D., Lachman, H.M. (2017).
- 904 Transcriptome analysis of microglia in a mouse model of Rett syndrome: differential expression
- of genes associated with microglia/macrophage activation and cellular stress. Mol. Autism 8, 17017-0134-z. eCollection 2017.
- 72. Jeong J, Li Y, Roche KW. CaMKII Phosphorylation Regulates Synaptic Enrichment of
- 908 Shank3. eNeuro. 2021 Feb 9:ENEURO.0481-20.2021. doi: 10.1523/ENEURO.0481-20.2021.
- 909 73. Lee, K., Vyas, Y., Garner, C.C., Montgomery, J.M. (2019). Autism-associated Shank3
- 910 mutations alter mGluR expression and mGluR-dependent but not NMDA receptor-dependent
- 911 long-term depression. Synapse 73, e22097.
- 912 74. Duffney, L.J., Wei, J., Cheng, J., Liu, W., Smith, K.R., Kittler, J.T., Yan, Z. (2013). Shank3
- 913 deficiency induces NMDA receptor hypofunction via an actin-dependent mechanism. J.
- 914 Neurosci. 33, 15767-15778.

- 915 75. Raynaud, F., Janossy, A., Dahl, J., Bertaso, F., Perroy, J., Varrault, A., Vidal, M., Worley,
- 916 P.F., Boeckers, T.M., Bockaert, J. et al. (2013). Shank3-Rich2 interaction regulates AMPA
- 917 receptor recycling and synaptic long-term potentiation. J. Neurosci. 33, 9699-9715.
- 918 76. Alexandrov, P.N., Zhao, Y., Jaber, V., Cong, L., Lukiw, W.J. (2017). Deficits in the Proline-
- Rich Synapse-Associated Shank3 Protein in Multiple Neuropsychiatric Disorders. Front. Neurol.
  8, 670.
- 77. Redin, C., Gerard, B., Lauer, J., Herenger, Y., Muller, J., Quartier, A., Masurel-Paulet, A.,
- Willems, M., Lesca, G., El-Chehadeh, S. et al. (2014). Efficient strategy for the molecular
- diagnosis of intellectual disability using targeted high-throughput sequencing. J. Med. Genet.
- 924 78. Leblond, C.S., Nava, C., Polge, A., Gauthier, J., Huguet, G., Lumbroso, S., Giuliano, F.,
- 925 Stordeur, C., Depienne, C., Mouzat, K. et al. (2014). Meta-analysis of SHANK Mutations in
- Autism Spectrum Disorders: a gradient of severity in cognitive impairments. PLoS Genet. 10,
- 927 e1004580.
- 928 79. Guilmatre, A., Huguet, G., Delorme, R., Bourgeron, T. (2014). The emerging role of SHANK
  929 genes in neuropsychiatric disorders. Dev. Neurobiol. 74, 113-122.
- 80. Bey, A.L., Gorman, M.P., Gallentine, W., Kohlenberg, T.M., Frankovich, J., Jiang, Y.H., Van
- Haren, K. (2020). Subacute Neuropsychiatric Syndrome in Girls With SHANK3 Mutations
- Responds to Immunomodulation. Pediatrics 145, e20191490. doi: 10.1542/peds.2019-1490.
- 81. Kohlenberg, T.M., Trelles, M.P., McLarney, B., Betancur, C., Thurm, A., Kolevzon, A.
- 934 (2020).Psychiatric illness and regression in individuals with Phelan-McDermid syndrome. J
- 935 Neurodev Disord Feb 12;12(1):7.
- 82. Berryer, M.H., Hamdan, F.F., Klitten, L.L., Moller, R.S., Carmant, L., Schwartzentruber, J.,
- 937 Patry, L., Dobrzeniecka, S., Rochefort, D., Neugnot-Cerioli, M. et al. (2013). Mutations in

- 938 SYNGAP1 cause intellectual disability, autism, and a specific form of epilepsy by inducing
- haploinsufficiency. Hum. Mutat. 34, 385-394.
- 940 83. Santos-Gómez, A., Miguez-Cabello, F., García-Recio, A., Locubiche, S., García-Díaz, R.,
- 941 Soto, V., Guerrero-López, R., Juliá-Palacios, N., Ciruela, F., García-Cazorla, Á. et al. (2020).
- 942 Disease-associated GRIN protein truncating variants trigger NMDA receptor loss-of-function.
- 943 Hum. Mol. Genet.
- 84. Myers, S.J., Yuan, H., Kang, J.Q., Tan, F.C.K., Traynelis, S.F., Low, C.M. (2019). Distinct
- roles of GRIN2A and GRIN2B variants in neurological conditions. F1000Res 8,
- 946 10.12688/f1000research.18949.1. eCollection 2019.
- 85. Strehlow, V., Heyne, H.O., Vlaskamp, D.R.M., Marwick, K.F.M., Rudolf, G., de Bellescize,
- J., Biskup, S., Brilstra, E.H., Brouwer, O.F., Callenbach, P.M.C. et al. (2019). GRIN2A-related
- disorders: genotype and functional consequence predict phenotype. Brain 142, 80-92.
- 86. Liao, X., Li, Y. (2020). Genetic associations between voltage-gated calcium channels and
- autism spectrum disorder: a systematic review. Mol. Brain 13, 96-020-00634-0.
- 952 87. Araki, Y., Hong, I., Gamache, T.R., Ju, S., Collado-Torres, L., Shin, J.H., Huganir, R.L.
- 953 (2020). SynGAP isoforms differentially regulate synaptic plasticity and dendritic development.
- 954 Elife 9, 10.7554/eLife.56273.
- 88. Li, J., Zhang, J., Tang, W., Mizu, R.K., Kusumoto, H., XiangWei, W., Xu, Y., Chen, W.,
- Amin, J.B., Hu, C. et al. (2019). De novo GRIN variants in NMDA receptor M2 channel pore-
- forming loop are associated with neurological diseases. Hum. Mutat. 40, 2393-2413.
- 89. Ryan, T.J., Kopanitsa, M.V., Indersmitten, T., Nithianantharajah, J., Afinowi, N.O., Pettit, C.,
- 959 Stanford, L.E., Sprengel, R., Saksida, L.M., Bussey, T.J. et al. (2013). Evolution of GluN2A/B

960 cytoplasmic domains diversified vertebrate synaptic plasticity and behavior. Nat. Neurosci. 16,961 25-32.

- 962 90. Seo, B.A., Lee, J.H., Kim, H.M., Kang, M.G. (2018). Neuronal calcium channel α(1) subunit
- <sup>963</sup> interacts with AMPA receptor, increasing its cell surface localisation. Biochem. Biophys. Res.
- 964 Commun. 498, 402-408.
- 965 91. SnowdenJ.A., Badoglio, M., Alexander, T. (2019). The rise of autologous HCT for
- autoimmune diseases: what is behind it and what does it mean for the future of treatment? An
- <sup>967</sup> update on behalf of the EBMT Autoimmune Diseases Working Party. Expert Rev Clin Immunol.
- 968 2019 Oct;15(10):981-985.
- 969 92. Kristinsson, S.Y., Landgren, O., Sjöberg, J., Turesson, I., Björkholm, M., Goldin, L.R. (2009).
- Autoimmunity and risk for Hodgkin's lymphoma by subtype. Haematologica 94, 1468-1469.
- 971 93. Urayama, K.Y., Jarrett, R.F., Hjalgrim, H., Diepstra, A., Kamatani, Y., Chabrier, A.,
- 972 Gaborieau, V., Boland, A., Nieters, A., Becker, N. et al. (2012). Genome-wide association study
- of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J. Natl.
- 974 Cancer Inst. 104, 240-253.
- 975 94. Nakayama, S., Yokote, T., Hiraoka, N., Nishiwaki, U., Hanafusa, T., Nishimura, Y., Tsuji, M.
- 976 (2016). Role of mast cells in fibrosis of classical Hodgkin lymphoma. Int. J. Immunopathol.
- 977 Pharmacol. 29, 603-611.
- 978 95. Nanda, H., Ponnusamy, N., Odumpatta, R., Jeyakanthan, J., Mohanapriya, A. (2020).
- 979 Exploring genetic targets of psoriasis using genome wide association studies (GWAS) for drug
- 980 repurposing. 3 Biotech 10, 43-019-2038-4. Epub 2020 Jan 10.
- 981 96. Li, B., Huang, L., Lv, P., Li, X., Liu, G., Chen, Y., Wang, Z., Qian, X., Shen, Y., Li, Y. et al.
- 982 (2020). The role of Th17 cells in psoriasis. Immunol. Res. 68, 296-309.

- 983 97. Wang, T., Hoekzema, K., Vecchio, D., Wu, H., Sulovari, A., Coe, B.P., Gillentine, M.A.,
- 984 Wilfert, A.B., Perez-Jurado, L.A., Kvarnung, M. et al. (2020). Large-scale targeted sequencing
- identifies risk genes for neurodevelopmental disorders. Nat. Commun. 11, 4932-020-18723-y.
- 986 98. Li, X., Guo, S., Liu, K., Zhang, C., Chang, H., Yang, W., Rong, S., Hu, Q., Cui, J., Wang, F.
- 987 et al. (2020). GABRG2 Deletion Linked to Genetic Epilepsy with Febrile Seizures Plus Affects
- the Expression of GABA(A) Receptor Subunits and Other Genes at Different Temperatures.
- 989 Neuroscience 438, 116-136.
- 990 99. Jiang, Y.L., Song, C., Wang, Y., Zhao, J., Yang, F., Gao, Q., Leng, X., Man, Y., Jiang, W.
- 991 (2020). Clinical Utility of Exome Sequencing and Reinterpreting Genetic Test Results in
- 992 Children and Adults With Epilepsy. Front. Genet. 11, 591434.
- 100. Li, J., Liu, Y., Li, Q., Huang, X., Zhou, D., Xu, H., Zhao, F., Mi, X., Wang, R., Jia, F. et al.
- 994 (2020). Mutation in ε-Sarcoglycan Induces a Myoclonus-Dystonia Syndrome-Like Movement
   995 Disorder in Mice. Neurosci. Bull.
- 101. Yankova, G., Bogomyakova, O., Tulupov, A. (2021). The glymphatic system and
- 997 meningeal lymphatics of the brain: new understanding of brain clearance. Rev. Neurosci.
- 998 102. Manouchehrian, O., Ramos, M., Bachiller, S., Lundgaard, I., Deierborg, T. (2021). Acute
- systemic LPS-exposure impairs perivascular CSF distribution in mice. J. Neuroinflammation 18,
  34-021-02082-6.
- 1001 103. Nedergaard, M., Goldman, S.A. (2020). Glymphatic failure as a final common pathway to
  1002 dementia. Science 370, 50-56.
- 1003 104. LeDoux, M.S. (2020). Population Prevalence of Deleterious SGCE Variants. Tremor Other
  1004 Hyperkinet Mov. (N. Y) 10, 50.

- 1005 105. Delgado-Alvarado, M., Matilla-Dueñas, A., Altadill-Bermejo, A., Setién, S., Misiego-Peral,
- 1006 M., Sánchez-de la Torre, J.R., Corral-Juan, M., Riancho, J. (2020). A novel SGCE variant is
- associated with myoclonus-dystonia with phenotypic variability. Neurol. Sci. 41, 3779-3781.
- 1008 106. Peall, K.J., Smith, D.J., Kurian, M.A., Wardle, M., Waite, A.J., Hedderly, T., Lin, J.P.,
- 1009 Smith, M., Whone, A., Pall, H. et al. (2013). SGCE mutations cause psychiatric disorders:
- 1010 clinical and genetic characterization. Brain 136, 294-303.
- 1011 107. Fernández-Marmiesse, A., Kusumoto, H., Rekarte, S., Roca, I., Zhang, J., Myers, S.J.,
- 1012 Traynelis, S.F., Couce, M.L., Gutierrez-Solana, L., Yuan, H. (2018). A novel missense mutation
- in GRIN2A causes a nonepileptic neurodevelopmental disorder. Mov. Disord. 33, 992-999.
- 1014 108. Coco , R., Raicu, F., Băjenaru, O.L., Olaru, I., Dumitrescu, L., Popescu, B.O. (2020).
- 1015 CACNA1B gene variants in adult-onset isolated focal dystonia. Neurol. Sci.
- 1016 109. Klitten, L.L., Møller, R.S., Nikanorova, M., Silahtaroglu, A., Hjalgrim, H., Tommerup, N.
- 1017 (2011). A balanced translocation disrupts SYNGAP1 in a patient with intellectual disability,
- speech impairment, and epilepsy with myoclonic absences (EMA). Epilepsia 52, e190-3.
- 1019 110. von Stülpnagel, C., Hartlieb, T., Borggräfe, I., Coppola, A., Gennaro, E., Eschermann, K.,
- 1020 Kiwull, L., Kluger, F., Krois, I., Møller, R.S. et al. (2019). Chewing induced reflex seizures
- 1021 ("eating epilepsy") and eye closure sensitivity as a common feature in pediatric patients with
- 1022 SYNGAP1 mutations: Review of literature and report of 8 cases. Seizure 65, 131-137.
- 1023 111. Manthiram, K., Zhou, Q., Aksentijevich, I., Kastner, D.L. (2017). The monogenic
- 1024 autoinflammatory diseases define new pathways in human innate immunity and inflammation.
- 1025 Nat. Immunol. 18, 832-842.
- 1026 112. Taniguchi, K., Karin, M. (2018). NF-κB, inflammation, immunity and cancer: coming of age.
- 1027 Nat. Rev. Immunol. 18, 309-324.

- 1028 113. Liu, T., Zhang, L., Joo, D., Sun, S.C. (2017). NF-κB signaling in inflammation. Signal.
- 1029 Transduct Target Ther. 2, 17023.
- 1030 114. Comeau, K., Paradism P., Schiffrin, E.L. (2000). Human and murine memory gammadelta
- 1031 T cells: Evidence for acquired immune memory in bacterial and viral infections and
- 1032 autoimmunity. Cell Immunol. Nov;357:104217. doi: 10.1016/j.cellimm.2020.104217. Epub 2020
- 1033 Sep 16.
- 1034 115. Li, Y., Zhang, Y., Zeng, X. (2021). γδ T Cells Participating in Nervous Systems: A Story of
- Jekyll and Hyde. Front Immunol. Mar 31; 12:656097. Published online 2021 Mar 31. doi:
- 1036 10.3389/fimmu.2021.656097
- 1037 116. Alves de Lima, K., Rustenhoven, J., Da Mesquita, S., Wall, M., Salvador, A.F., Smirnov, I.,
- Cebinelli, G.M., Mamuladze, T., Baker, W., Papadopoulos, Z, et al. (2020). Meningeal γδ T cells
  regulate anxiety-like behavior via IL-17a signaling in neurons. Nat Immunol. Nov;21(11):1421-
- 1040 **1429**.
- 1041 117. Korzh, V. (2018). Development of brain ventricular system. Cell Mol,. Life Sci. 75, 375-383.
- 1042 118. Javed, K., Reddy, V., Lui, F. (2021). Neuroanatomy, Choroid Plexus. In StatPearls,
- 1043 Anonymous (Treasure Island (FL): StatPearls Publishing LLC).
- 1044 119. Hubert, V., Dumot, C., Ong, E., Amaz, C., Canet-Soulas, E., Chauveau, F., Wiart, M.
- 1045 (2019). MRI coupled with clinically-applicable iron oxide nanoparticles reveals choroid plexus
- involvement in a murine model of neuroinflammation. Sci. Rep. 9, 10046-019-46566-1.
- 1047 120. Prinz, M., Masuda, T., Wheeler, M.A., Quintana, F.J. (2021). Microglia and Central
- 1048 Nervous System-Associated Macrophages-From Origin to Disease Modulation. Annu. Rev.
- 1049 Immunol.

- 1050 121. Huang, X., Hussain, B., Chang, J. (2021). Peripheral inflammation and blood-brain barrier
- 1051 disruption: effects and mechanisms. CNS Neurosci. Ther. 27, 36-47.
- 1052 122. Earl, R.K., Turner, T.N., Mefford, H.C., Hudac, C.M., Gerdts, J., Eichler, E.E., Bernier, R.A.
- 1053 (2017). Clinical phenotype of ASD-associated DYRK1A haploinsufficiency. Mol. Autism 8, 54-
- 1054 017-0173-5. eCollection 2017.
- 1055 123. O'Roak, B.J., Vives, L., Fu, W., Egertson, J.D., Stanaway, I.B., Phelps, I.G., Carvill, G.,
- 1056 Kumar, A., Lee, C., Ankenman, K. et al. (2012). Multiplex targeted sequencing identifies
- recurrently mutated genes in autism spectrum disorders. Science 338, 1619-1622.
- 1058 124. Dang, T., Duan, W.Y., Yu, B., Tong, D.L., Cheng, C., Zhang, Y.F., Wu, W., Ye, K., Zhang,
- 1059 W.X., Wu, M. et al. (2018). Autism-associated Dyrk1a truncation mutants impair neuronal
- dendritic and spine growth and interfere with postnatal cortical development. Mol. Psychiatry 23,747-758.
- 1062 125. Cerboni, S., Gehrmann, U., Preite, S., Mitra, S. (2020). Cytokine-regulated Th17 plasticity
  1063 in human health and diseases. Immunology.
- 1064 126. Cerboni, S., Gehrmann, U., Preite, S., Mitra, S. (2020). Cytokine-regulated Th17 plasticity
- 1065 in human health and diseases. Immunology.
- 1066 127. Zhang, R., Miao, J., Zhu, P. (2020). Regulatory T cell heterogeneity and therapy in
- 1067 autoimmune diseases. Autoimmun. Rev., 102715.
- 1068 128. Rosado-Sánchez, I., Levings, M.K. (2020). Building a CAR-Treg: Going from the basic to
- the luxury model. Cell. Immunol. 358, 104220.
- 1070 129. Khor, B., Gagnon, J.D., Goel, G., Roche, M.I., Conway, K.L., Tran, K., Aldrich, L.N.,
- 1071 Sundberg, T.B., Paterson, A.M., Mordecai, S. et al. (2015). The kinase DYRK1A reciprocally
- regulates the differentiation of Th17 and regulatory T cells. Elife 4, 10.7554/eLife.05920.

- 1073 130. Platt, M.P., Bolding, K.A., Wayne, C.R., Chaudhry, S., Cutforth, T., Franks, K.M., Agalliu,
- 1074 D. (2020). Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of
- 1075 postinfectious autoimmune encephalitis. Proc. Natl. Acad. Sci. U. S. A. 117, 6708-6716.
- 1076 131. Cutforth, T., DeMille, M.M., Agalliu, I., Agalliu, D. (2016). CNS autoimmune disease after
- 1077 Streptococcus pyogenes infections: animal models, cellular mechanisms and genetic factors.
- 1078 Future Neurol. 11, 63-76.
- 1079 132. Dileepan, T., Smith, E.D., Knowland, D., Hsu, M., Platt, M., Bittner-Eddy, P., Cohen, B.,
- 1080 Southern, P., Latimer, E., Harley, E. et al. (2016). Group A Streptococcus intranasal infection
- promotes CNS infiltration by streptococcal-specific Th17 cells. J. Clin. Invest. 126, 303-317.
- 1082 133. Choi, D.W., Na, W., Kabir, M.H., Yi, E., Kwon, S., Yeom, J., Ahn, J.W., Choi, H.H., Lee, Y.,
- 1083 Seo, K.W. et al. (2013). WIP1, a homeostatic regulator of the DNA damage response, is

targeted by HIPK2 for phosphorylation and degradation. Mol. Cell 51, 374-385.

- 1085 134. Xu, L., Fang, H., Xu, D., Wang, G. (2020). HIPK2 sustains inflammatory cytokine
- production by promoting endoplasmic reticulum stress in macrophages. Exp. Ther. Med. 20,1087 171.
- 1088 135. Li, R., Shang, J., Zhou, W., Jiang, L., Xie, D., Tu, G. (2018). Overexpression of HIPK2

attenuates spinal cord injury in rats by modulating apoptosis, oxidative stress, and inflammation.
Biomed. Pharmacother. 103, 127-134.

- 1091 136. Lewin, A.B., Storch, E.A., Murphy, T.K. (2011). Pediatric autoimmune neuropsychiatric
- 1092 disorders associated with Streptococcus in identical siblings. J. Child Adolesc.
- 1093 Psychopharmacol. 21, 177-182.
- 1094 137. Gan, L., O'Hanlon, T.P., Gordon, A.S., Rider, L.G., Miller, F.W., Burbelo, P.D. (2014).
- 1095 Twins discordant for myositis and systemic lupus erythematosus show markedly enriched

- autoantibodies in the affected twin supporting environmental influences in pathogenesis. BMC
  Musculoskelet. Disord. 15, 67-2474-15-67.
- 1098 138. Moretti, R., Pansiot, J., Bettati, D., Strazielle, N., Ghersi-Egea, J.F., Damante, G., Fleiss,
- 1099 B., Titomanlio, L., Gressens, P. (2015). Blood-brain barrier dysfunction in disorders of the
- 1100 developing brain. Front. Neurosci. 9, 40.
- 1101 139. Huett, A., Leong, J.M., Podolsky, D.K., Xavier, R.J. (2009). The cytoskeletal scaffold
- 1102 Shank3 is recruited to pathogen-induced actin rearrangements. Exp. Cell Res. 315, 2001-2011.
- 1103 140. Zhen, H., Zhao, L., Ling, Z., Kuo, L., Xue, X., Feng, J. (2018). Wip1 regulates blood-brain
- barrier function and neuro-inflammation induced by lipopolysaccharide via the sonic hedgehog
- signaling signaling pathway. Mol. Immunol. 93, 31-37.
- 1106 141. Goasdoué, K., Miller, S.M., Colditz, P.B., Björkman, S.T. (2017). Review: The blood-brain
- barrier; protecting the developing fetal brain. Placenta 54, 111-116.
- 1108 142. Lombardo, M.V., Moon, H.M., Su, J., Palmer, T.D., Courchesne, E., Pramparo, T. (2018).
- 1109 Maternal immune activation dysregulation of the fetal brain transcriptome and relevance to the
- 1110 pathophysiology of autism spectrum disorder. Mol. Psychiatry 23, 1001-1013.
- 1111 143. Spann, M.N., Monk, C., Scheinost, D., Peterson, B.S. (2018). Maternal Immune Activation
- 1112 During the Third Trimester Is Associated with Neonatal Functional Connectivity of the Salience
- 1113 Network and Fetal to Toddler Behavior. J. Neurosci. 38, 2877-2886.
- 1114 144. Ducharme, G., Lowe, G.C., Goutagny, R., Williams, S. (2012). Early alterations in
- 1115 hippocampal circuitry and theta rhythm generation in a mouse model of prenatal infection:
- implications for schizophrenia. PLoS One 7, e29754.

- 1117 145. Arnold, S.E., Franz, B.R., Gur, R.C., Gur, R.E., Shapiro, R.M., Moberg, P.J., Trojanowski,
- 1118 J.Q. (1995). Smaller neuron size in schizophrenia in hippocampal subfields that mediate
- 1119 cortical-hippocampal interactions. Am. J. Psychiatry 152, 738-748.
- 1120 146. Benes, F.M. (2011). Regulation of cell cycle and DNA repair in post-mitotic GABA neurons
- in psychotic disorders. Neuropharmacology 60, 1232-1242.
- 1122 147. Benes, F.M., Lim, B., Matzilevich, D., Subburaju, S., Walsh, J.P. (2008). Circuitry-based
- gene expression profiles in GABA cells of the trisynaptic pathway in schizophrenics versus
- 1124 bipolars. Proc. Natl. Acad. Sci. U. S. A. 105, 20935-20940.
- 1125 148. Benes, F.M., Lim, B., Matzilevich, D., Walsh, J.P., Subburaju, S., Minns, M. (2007).
- 1126 Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc.
- 1127 Natl. Acad. Sci. U. S. A. 104, 10164-10169.
- 1128 149. Smith, S.E., Li, J., Garbett, K., Mirnics, K., Patterson, P.H. (2007). Maternal immune
- activation alters fetal brain development through interleukin-6. J. Neurosci. 27, 10695-10702.
- 1130 150. Bauman, M.D., Iosif, A.M., Smith, S.E., Bregere, C., Amaral, D.G., Patterson, P.H. (2014).
- 1131 Activation of the maternal immune system during pregnancy alters behavioral development of
- 1132 rhesus monkey offspring. Biol. Psychiatry 75, 332-341.
- 1133 151. Meyer, U., Feldon, J., Fatemi, S.H. (2009). In-vivo rodent models for the experimental
- investigation of prenatal immune activation effects in neurodevelopmental brain disorders.
- 1135 Neurosci. Biobehav. Rev. 33, 1061-1079.
- 1136 152. Oskvig, D.B., Elkahloun, A.G., Johnson, K.R., Phillips, T.M., Herkenham, M. (2012).
- 1137 Maternal immune activation by LPS selectively alters specific gene expression profiles of
- 1138 interneuron migration and oxidative stress in the fetus without triggering a fetal immune
- response. Brain Behav. Immun. 26, 623-634.

- 1140 153. Lünemann, J.D., Nimmerjahn, F., Dalakas, M.C. (2015). Intravenous immunoglobulin in
- neurology--mode of action and clinical efficacy. Nat. Rev. Neurol. 11, 80-89.
- 1142 154. Norris, P.A.A., Kaur, G., Lazarus, A.H. (2020). New insights into IVIg mechanisms and
- alternatives in autoimmune and inflammatory diseases. Curr. Opin. Hematol. 27, 392-398.
- 1144 155. Bayry, J., Thirion, M., Misra, N., Thorenoor, N., Delignat, S., Lacroix-Desmazes, S., Bellon,
- 1145 B., Kaveri, S., Kazatchkine, M.D. (2003). Mechanisms of action of intravenous immunoglobulin
- in autoimmune and inflammatory diseases. Neurol. Sci. 24 Suppl 4, S217-21.
- 1147 156. Poetsch, V., Neuhaus, W., Noe, C.R. (2010). Serum-derived immunoglobulins neutralize
- adverse effects of amyloid-beta peptide on the integrity of a blood-brain barrier in vitro model. J.
- 1149 Alzheimers Dis. 21, 303-314.
- 1150 157. Jones, H.F., Ho, A.C.C., Sharma, S., Mohammad, S.S., Kothur, K., Patel, S., Brilot, F.,
- 1151 Guastella, A.J., Dale, R.C., Immune-Neurodevelopment (Imm-Nd) Study Group. (2019).
- 1152 Maternal thyroid autoimmunity associated with acute-onset neuropsychiatric disorders and
- 1153 global regression in offspring. Dev. Med. Child Neurol. 61, 984-988.
- 1154 158. Lin, J.R., Cai, Y., Zhang, Q., Zhang, W., Nogales-Cadenas, R., Zhang, Z.D. (2016).
- 1155 Integrated Post-GWAS Analysis Sheds New Light on the Disease Mechanisms of
- 1156 Schizophrenia. Genetics 204, 1587-1600.
- 1157 159. García-Cuesta, E.M., Santiago, C.A., Vallejo-Díaz, J., Juarranz, Y., Rodríguez-Frade, J.M.,
- 1158 Mellado, M. (2019). The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases.
- 1159 Front. Endocrinol. (Lausanne) 10, 585.
- 1160 160. Sekar, A., Bialas, A.R., de Rivera, H., Davis, A., Hammond, T.R., Kamitaki, N., Tooley, K.,
- 1161 Presumey, J., Baum, M., Van Doren, V. et al. (2016). Schizophrenia risk from complex variation
- of complement component 4. Nature 530, 177-183.

- 1163 161. Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological
- insights from 108 schizophrenia-associated genetic loci. Nature 511, 421-427.
- 1165 162. Hafizi, S., Tabatabaei, D., Lai, M.C. (2019). Review of Clinical Studies Targeting
- 1166 Inflammatory Pathways for Individuals With Autism. Front. Psychiatry. 10, 849.
- 1167 163. Atladóttir, H.O., Pedersen, M.G., Thorsen, P., Mortensen, P.B., Deleuran, B., Eaton, W.W.,
- 1168 Parner, E.T. (2009). Association of family history of autoimmune diseases and autism spectrum
- 1169 disorders. Pediatrics 124, 687-694.
- 1170 164. Lyall, K., Ames, J.L., Pearl, M., Traglia, M., Weiss, L.A., Windham, G.C., Kharrazi, M.,
- 1171 Yoshida, C.K., Yolken, R., Volk, H.E. et al. (2021). A profile and review of findings from the
- 1172 Early Markers for Autism study: unique contributions from a population-based case-control
- 1173 study in California. Mol. Autism 12, 24-021-00429-7.
- 1174 165. Dantzer, R. (2018). Neuroimmune Interactions: From the Brain to the Immune System and
  1175 Vice Versa. Physiol. Rev. 98, 477-504.
- 1176 166. Quagliariello, A., Del Chierico, F., Russo, A., Reddel, S., Conte, G., Lopetuso, L.R., Ianiro,
- 1177 G., Dallapiccola, B., Cardona, F., Gasbarrini, A. et al. (2018). Gut Microbiota Profiling and Gut-
- 1178 Brain Crosstalk in Children Affected by Pediatric Acute-Onset Neuropsychiatric Syndrome and
- 1179 Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections.
- 1180 Front. Microbiol. 9, 675.
- 1181 167. Pellegrini, C., Antonioli, L., Calderone, V., Colucci, R., Fornai, M., Blandizzi, C. (2020).
- 1182 Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of
- 1183 microbiota-gut-brain communications? Prog. Neurobiol. 191, 101806.
- 1184 168. Loffredo, L., Spalice, A., Salvatori, F., De Castro, G., Guido, C.A., Zicari, A.M., Ciacci, P.,
- 1185 Battaglia, S., Brindisi, G., Ettorre, E. et al. (2020). Oxidative stress and gut-derived

- 1186 lipopolysaccharides in children affected by paediatric autoimmune neuropsychiatric disorders
- associated with streptococcal infections. BMC Pediatr. 20, 127-020-02026-8.
- 1188 169. Sauer, A.K., Bockmann, J., Steinestel, K., Boeckers, T.M., Grabrucker, A.M. (2019).
- 1189 Altered Intestinal Morphology and Microbiota Composition in the Autism Spectrum Disorders
- Associated SHANK3 Mouse Model. Int. J. Mol. Sci. 20, 2134. doi: 10.3390/ijms20092134.
- 1191 170. Wei, S.C., Yang-Yen, H.F., Tsao, P.N., Weng, M.T., Tung, C.C., Yu, L.C.H., Lai, L.C.,
- Hsiao, J.H., Chuang, E.Y., Shun, C.T. et al. (2017). SHANK3 Regulates Intestinal Barrier
- 1193 Function Through Modulating ZO-1 Expression Through the PKCε-dependent Pathway.
- 1194 Inflamm. Bowel Dis. 23, 1730-1740.
- 1195 171. Rodrigues, F., Hentgen, V., Bachmeyer, C., Kone-Paut, I., Belot, A., Grateau, G.,
- 1196 Sarrabay, G., Georgin-Lavialle, S. (2018). [NLRC4 associated autoinflammatory diseases: A
- systematic review of the current literature]. Rev Med Interne. 2018 Apr;39(4):279-286.2
- 1198 Opipari, A., Franchi, L,. Role of inflammasomes in intestinal inflammation and Crohn's disease.
- 1199 (2015). Inflamm Bowel Dis. Jan;21(1):173-81.
- 1200 173. Tse, J.K.Y. (2017). Gut Microbiota, Nitric Oxide, and Microglia as Prerequisites for
- 1201 Neurodegenerative Disorders. ACS Chem. Neurosci. 8, 1438-1447.
- 1202 174. Esposito, G., Sarnelli, G., Capoccia, E., Cirillo, C., Pesce, M., Lu, J., Calì, G., Cuomo, R.,
- 1203 Steardo, L. (2016). Autologous transplantation of intestine-isolated glia cells improves
- neuropathology and restores cognitive deficits in  $\beta$  amyloid-induced neurodegeneration. Sci.
- 1205 Rep. 6, 22605.
- 175. Niesler, B., Kuerten, S., Demir, I.E., Schäfer, K.H. (2021). Disorders of the enteric nervous
  system a holistic view. Nat. Rev. Gastroenterol. Hepatol.

1208	176. Jakob, M.O., Murugan, S., Klose, C.S.N. (2020). Neuro-Immune Circuits Regulate Immune
1209	Responses in Tissues and Organ Homeostasis. Front. Immunol. 11, 308.
1210	177. Spear, E.T., Mawe, G.M. (2019). Enteric neuroplasticity and dysmotility in inflammatory
1211	disease: key players and possible therapeutic targets. Am. J. Physiol. Gastrointest. Liver
1212	Physiol. 317, G853-G861.
1213	
1215	
1214	Figure Legends
1215	Figure 1. Position of PANS ultra-rare variants within each candidate gene
1216	
1217	Figure 2. Heat map of LPS-mediated gene expression in microglia. Microarray gene expression
1218	data (GSE102482) from Greenhalgh et at. (reference 15) were analyzed to determine the
1219	expression pattern of a subset of 148 autism and pediatric immune disorder genes. The heat
1220	map shows the data obtained from RNA extracted from microglia grown on their own or co-
1221	cultured with peripheral macrophages. Arrows point to differentially expressed genes that are
1222	PANS candidates described in this report.
1223	
1224	Figure 3. Connectivity network. A connectivity network was generated for each candidate gene
1225	using IPA software. Two additional PANS candidate genes, MTHC2 and BID, identified by one
1226	of us (R.T.) are included. These will be described in a separate paper. Central to the network is
1227	the NF-κB complex transcriptional regulator hub, which connects to PPM1D, PLCG2, NLRC4,
1228	RAG1, BID, CHK2 and MTCH2. The PANS candidate genes not directly connected to NF- $\kappa$ B
1229	expression are those that are primarily expressed in the brain and cause neurodevelopmental
1230	disorders (CACNA1B, SYNGAP1, GRIN2A, SGCE, GABRG2, and SHANK3). See
1231	Supplemental Data for symbol key.
1232	
	51

- 1233 Figure 4. Single cell RNA-seq expression pattern of each PANS candidate gene in mouse
- adolescent brains (mouse brain atlas; see Web Resources)
- 1235
- 1236 Table Legends
- 1237 **Table 1.** Diagnostic criteria for PANS/PANDAS adapted from reference 3 and NIMH (see Web
- 1238 Resources)
- 1239 **Table 2.** Summary of cases. Patient demographics, genetic variants, and brief clinical
- 1240 description. Bold type highlights cases with comorbid neurodevelopmental disorders, red type
- 1241 highlights those with a history of recurrent infections. For complete patient histories, see
- 1242 Supplemental Note: Case Reports. Abbreviations: pathogenic (P); likely pathogenic (LP); variant
- 1243 of unknown significance (VUS). To protect patient confidentiality, ages are not included. Each
- 1244 case showed the first signs of PANS before the age of 10.

## PANS

I. Abrupt onset of obsessive-compulsive disorder or severely restricted food intake

II. Concurrent presence of additional neuropsychiatric symptoms with severe and acute onset from at least two of the following:

Anxiety

Emotional lability and/or depression

Irritability, aggression, and/or severely oppositional behaviors

Behavioral (developmental) regression

Deterioration in school performance (related to attention deficit/hyperactivity disorder [ADHD]-like symptoms, memory deficits, cognitive changes

Sensory or motor abnormalities

Somatic signs and symptoms, including sleep disturbances, enuresis, or urinary frequency

III. Symptoms are not better explained by a known neurologic or medical disorder

## PANDAS

I. Abrupt onset of clinically significant obsessions, compulsions and/or tics

II. Association with Group A Streptococcal infection

III. Pre-pubertal onset

IV. Relapsing-remitting course

V. Association with other neuropsychiatric symptoms including:

Severe separation anxiety

Generalized anxiety

Motoric hyperactivity, abnormal movements, and a sense of restlessness

Sensory abnormalities (sensitivity to light or sounds), distortions of visual perceptions, and occasionally, visual or auditory hallucinations

Difficulties concentrating, and loss of academic abilities, particularly in math and visual-spatial areas

Increased urinary frequency, or sense of urgency and/or a new onset of bed-wetting

Irritability, aggression, emotional lability.

Abrupt onset of depression with thoughts about suicide

Developmental regression, including temper tantrums, and handwriting deterioration

1246

Table 1

case	Sex	Gene	DATABASE	AC MG /Clinvar	DNA	PROTEIN	rsID	MAF	Significant co-morbidities (DD; ASD; movement disorder, epilepsy); other features of interest
1	F	PPM1D	Europe	V US	c.131C>G	p.S44W	rs373862041	0.0003	severe, chronic psychiatric symptoms; frequent infections, severe atopy
2	М	PPM1D	Europe	V US	c.131C>G	p.S44W	rs373862041	0.0003	severe, chronic psychiatric symptoms; frequent infections, severe atopy, sibling of case 1
4	М	CACNA1B	Europe	V US	c.390+1,48 bpins	unknown	rs370237172	0.017*	psoriasis, infections, Hodgkins disease; improve d PANS symptoms after autologous HSCT
3	м	CACNA1B	Europe	V US	c.390+1,48 bpins	unknown	rs370237172	0.017*	frequent infections, sibling of case 3
5	F	GABRG2	Europe	Р	c.649C>T	p.GIn217X	novel	0.000055	febrile seizures, family hx of autoimmune disease, frequent infections
6	М	GR IN 2A	Europe	V US	c.3578T>G	p.L1193W	rs75761674	0.0001	severe, chronic, fre quent infections, dyslexia, ADHD, and emotional problems,
7	М	PLCG2	Europe	V US	c.617A>G	p.Y206F	rs766231080	0.000008	ASD, chronic anxiety, insomnia, cognitive decline, frequent infections with fever
8	F	SYNGAP1	Europe	LP	c.3535A>T	p.Lys1179X	novel	<1e-6	ASD, language and motor delay
9	М	NLR C4	Europe	V US	c.772T>C	p.C258R	rs916856506	0.0000248	recurrent infection; incomplete-hippocampal inversion
10	F	SGCE	Europe	V US	c.450_452 del	p.I150de Ilso	rs886062522	<1e-6	family history psoriasis and other autoimmune problems
11	F	SGCE	USA	VUS/P	c.771_772deIAT	p.258fsX)	rs794727794	<1e-6	dyslexia prior to first PANS e pisode, recurrent pneumococcal infections
12	Μ	NLR C4	USA	V US	c.2309T>C	p.M770T	rs1264574917	0.000008	developmental de lay/ASD, recurrent pneumococcal infections
13	F	NLR C4	USA	V US	c.1799A>G	p.E600G	rs150950016	0.0002	atrial septal defect, marfaniod body habitus, normal CGH recurrent infections, elevated lgA, lgE, lgG2, lgG3 and lgG
14	М	RAG1	USA	VUS/P	c.256_257deIAA	p.K86fsX32	rs772962160	0.00024	non-verbal ASD, low lg2, lgG4, mannose-binding lectin deficiency, recurrent infections
15	М	RAG1	USA	LP/P	c.1286A>G	p.D429G	rs104894292	0.000006	non-verbal ASD, recurrent infections
16	F	RAG1	USA	V US	c.2515C>T	p.H839Y	rs 129 303 6892	0.000006	mutism as teengaer, recurrent infections, family history autommune disorders
17	F	SHANK3	USA	V US	c.4622C>T	P1541L	rs1329146990	<1e-6	severe OCD; also has NLRC4 c.928C>T, p.310X
18	М	SHANK3	USA	V US	c.3637dupG	p.1213fsX68	de novo	<1e-6	minimally verbal, autism, seizures, Phelan-McDermid Syndrome, severe OCD
19	F	SHANK3	USA	V US	c.4776dupC	p.T1593fs86	de novo	<1e-6	minimally verbal, autism, severe OCD
20	М	CHK2	USA	VUS	c.1229 de IC	T410fsX14	rs555607708	0.001	developmental delay, frequent infections

Table 2







Legend							
Complex							
Enzyme							
Group/Complex							
Ion Channel							
Kinase							
Phosphatase							
Transcription Regulator							
Transmembrane Receptor							
Other							
- Relationship							

\_\_\_\_\_

